2018 Thrombosis and Hemostasis Summit of North America (THSNA 2018)


Printable Program




March 6-8, 2018

San Diego, CA






Wednesday, March 7, 2018


7:00 - 4:30 PMHilton San Diego Airport/Harbor Island.
HTRS Trainee Workshop: Building a Career in Hemostasis and Thrombosis

8:00 - 4:30 PMHilton San Diego Airport/Harbor Island
HTRS/NASTH Research Colloquium: Developing a Sustainable Research Career in Hemostasis and Thrombosis

1:00 - 5:00 PMTorrey Pines
ISLH and NASCOLA Worskshop: What you should know before you order hemostasis and thrombosis lab tests and what should you know when you look at the results: An interactive session

1:00
Anticoagulant Monitoring
Chuck Eby
Washington University School of Medicine

1:30
Diagnostic Testing For Platelet Function Disorders And Rare Bleeding Disorders
Cathy Hayward
McMaster University

2:00
Factor Viii Inhibitor Measurement &Ndash; Preanalytic Considerations, Anticoagulation Monitoring Challenges, Laboratory Evaluation And Interpretation Of Heparin-Induced Thrombocytopenia (Hit) Assays, Diagnostic Testing For Platelet Function Disorders And Rare Bleeding Disorders,
Castellone,Eb Smock, Hayward

2:30
Lupus Anticoagulant With Hypoprothrombinemia
Chuck Eby
Washington University School of Medicine

3:00
Laboratory Evaluation And Interpretation Of Hit Assays
Kristi Smock
University of Utah

3:30
Measuring Heparin Levels – Preanalytic Considerations
Richard Marlar
University of New Mexico

4:00
Discrepant Hemophilia A
Dorothy Adcock
LabCorp Diagnostics

1:00 - 4:00 PMPresidio
Nursing Pre-Summit Workshop: Thrombosis and Hemostasis Patient Education: Kernels and Pearls

1:00
Pediatric Thrombosis
Jim Munn
University of Michigan

1:30
Inhibitor Prevention
Chrsitine Guelcher
Childrens National medical Center

2:00
How To Successfully Transition Patients Safely Home (Pediatric And Adult Perspective)
Carole Hennessey1, Lynn Oertel2
1Children's National Health System, 2Massachusetts General Hospital

2:30
Break

2:30
Developing A Management Plan To Incorporate Doacs Into What Was A Traditional Warfarin Clinic
Lynn Oertel
Massachusetts General Hospital

3:00
Adult Prophylaxis
Laurel McKernan
Dartmouth-Hitchcock

3:30
Ask The Experts
Moderator: Kim Schafer
University of California at Davis

1:00 - 5:00 PMPoint Loma
ATHN Research Workshop: Updates & Opportunities for Research Through ATHN 1:00 PM - 5:00 PM Part 1 (1-3 pm) is for current ATHN Investigators; Part 2 (3-5 pm) is open to all conference attendees

1:30 - 4:00 PMSanta Rosa
Hemophilia Alliance Workshop: Compliance, Audit, Operational Effectiveness and Enhancing your Pharmacy Program

3:00 - 5:00 PMLaguna
Platelet Disorder Support Association (PDSA) Workshop: ITP Treatment Choice with reference to Clinical Guidelines

7:00 - 9:00 PMMarriott Marquis- Marina Kitchen
THSNA Board Meeting



Thursday, March 8, 2018


8:30 - 10:15 AMGrand 5-7
Welcoming Remarks/ Opening Plenary

Chair(s): Michael Paidas, Shannon Carpenter, Cathy Hayward
8:30
Welcome Message
Scott Kaatz
THSNA President

8:45
Overview Of Gene Editing And Gene Therapy
J. Keith Joung
Massachusetts General Hospital/Harvard Medical School

9:15
Contemporary Gene Therapy In Hemostasis And Thrombosis
Katherine High
Spark Therapeutics

9:45
Bioethics Of Gene Editing And Gene Therapy
Jeffrey Kahn
Johns Hopkins Berman Institute of Bioethics

10:15 - 11:00 AMPacific Ballroom
Poster Session/Exhibits

P2
Age-Related Incidence Of Polypharmacy In A Warfarin Anticoagulated Veteran Population.
Tania Baranov, Linh Chan, Walter Crumpler, Alan Jacobson
VA Loma Linda Healthcare System, Loma Linda, CA, United States

P3
A Review Of Interventions To Increase Vena Cava Filter Retrieval Rates
Joshua D. Brown1, Amie J. Goodin1, Driss Raissi2
1University of Florida, Gainesville, FL, United States, 2University of Kentucky, Lexington, KY, United States

P4
Four Factor Prothrombin Concentrate Utilization At A Level 1 Trauma Center
Miles Grunvald, Loic Fabricant
University of Vermont College Of Medicine, Burlington, VT, United States

P5
Provider Comfort And Confidence With An Extended Inr Follow-Up Interval For Veteran Patients On Stable Doses Of Warfarin
Amanda Margolis1,2, Michael Nagy2, Rebecca Schoen3, Andrea Porter1,2
1University of Wisconsin-Madison School of Pharmacy, Madison, WI, United States, 2William S. Middleton Memorial VA Hospital, Madison, WI, United States, 3Texas Tech University Health Sciences Center, Dallas, TX, United States

P6
Oral Anticoagulant Dosing, Administration, And Storage: A Cross-Sectional Survey Of Canadian Health Care Providers
Siavash Piran1, Sam Schulman1, Mohamed Panju2, Menaka Pai1
1Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada, 2Department of Medicine, Division of General Internal Medicine, McMaster University, Hamilton, ON, Canada

P7
Research Database For The Multidisciplinary Clinic For Women With Bleeding Disorders
Grace Tang1, Georgina Floros2,3, Antonette Travas3, Jillian Baker4, Rachel Martin5, Filomena Meffe6, Michelle Sholzberg1,3,7
1Department of Hematology, St. Michael's Hospital, Toronto, ON, Canada, 2Department of Nursing, St. Michael’s Hospital, Toronto, ON, Canada, 3Toronto and Central Ontario Comprehensive Hemophilia Program, St. Michael’s Hospital, Toronto, ON, Canada, 4Department of Pediatrics, St. Michael’s Hospital, Toronto, ON, Canada, 5Department of Anesthesia, St. Michael’s Hospital, Toronto, ON, Canada, 6Department of Obstetrics and Gynecology, St. Michael’s Hospital, Toronto, ON, Canada, 7Departments of Medicine and Laboratory Medicine and Pathobiology, St. Michael’s Hospital, Toronto, ON, Canada

P8
Characteristics Of High Utilizers Receiving Anticoagulation
Sara Turbow1, Miachael Knauss2, Niambi Vantress2, Mikhail Y Akbashev1
1Emory University, Atlanta, GA, United States, 2Grady Memorial Hospital, Atlanta, GA, United States

P9
Contact Pathway Inhibition By Corn Trypsin Inhibitor Does Not Affect Thrombin Generation Profiles In Plasma From Healthy Children
Rida Abid, Ravindra Sarode, Neethu Menon, Andrew Austin, Ayesha Zia
The University of Texas Southwestern Medical Center, Dallas, TX, United States

P10
Recommendation On The Use And Management Of Emicizumab For Patients With Hemophilia A With Inhibitors
Michael U Callaghan1, Amy L Dunn2, Rebecca Kruse-Jarres3, Guy Young4, Steven Pipe5
1Children’s Hospital of Michigan, Detroit, MI, United States, 2Nationwide Children's Hospital, Columbus, OH, United States, 3Bloodworks Northwest, Seattle, WA, United States, 4Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, United States, 5Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, United States

P11
Rotational Thromboelastometry Applied To Preclinical Models: Minipig Acute Radiation Syndrome And Ex-Vivo Pharmacological Investigations
Polly Chang1, James Bakke1, Janet Gahagen1, Karen Wong2, Camille St-Jean3, Simon Authier2, 3
1SRI Biosciences, Menlo Park, CA, United States, 2CiToxLAB, Laval, QC, Canada, 3Faculty of Veterinary Medicine, University of Montreal, St-Hyacinthe, QC, Canada

P12
Challenges In Measuring Coagulation Factors In Animal Models Of Acute Radiation Syndrome
John Esker, Ashley Cecere, Erika Davies, Mary Homer
Biomedical Advanced Research and Development Authority (BARDA), Washington, DC, DC, United States

P13
Biochemical And Pharmacological Differentiation Of Apc And Recombinant Thrombomodulin With Reference To The Effect On The Hemostatic And Fibrinolytic Processes
Jawed Fareed1, Debra Hoppensteadt1, Omer Iqbal1, Schuharazad Abro1, Destini Clarizio1, Kosuke Tanaka2, Kazuhisa Tsuruta2
1Loyola University Chicago, Maywood, IL, United States, 2Asahi Kasei Pharma America, Waltham, MA, United States

P14
Skeletal Muscle Myosin Has Pro-Hemostatic Activity In Vivo.
Mohammed Hayat, Hiroshi Deguchi, Tine Wyseure, Laurent O. Mosnier, John H. Griffin
The Scripps Research Institute, La Jolla, CA, United States

P15
Do Us Clinicians View &Ldquo;Portability Features&Rdquo; As Meaningful Fviii Product Attributes? A Conjoint Analysis.
Neeraj N. Iyer1, Yan Wang2, Jennifer Kirschenbaum2, Alison Currie2, Natalia Holot1, Juliana Setyawan1
1Novo Nordisk, Inc., Plainsboro, NJ, United States, 2WG Group, New York, NY, United States

P17
Presence Of Maximal Lysis On Fibtem Tracing Could Overestimate Fibrinogen In Plasma By Maximum Clot Firmness Value
Vadim Kostousov1,2, Amir Shamshirsaz 1,2, Hadi Erfani1,2, Karin Fox1, Karen Bruzdoski1,2, Shiu-Ki (Rocky) Hui1,2, Jun Teruya1,2
1Texas Children's Hospital, Houston, TX, United States, 2Baylor College of Medicine, Houston, TX, United States

P18
Real-World Healthcare Resource Utilization Of Rfviiifc Versus Rfviii In Hemophilia A
Nanxin (Nick) Li, Desilu Glazebrook, Jun Su
Bioverativ Therapeutics Inc, Waltham, MA, United States

P20
The Effect Of Blood Hypercoagulability On The Outcome Of In Vitro Fertilization: A Prospective Longitudinal Observational Study
Stella Salta1,2, Eleftheria Lefkou2, Loula Papageorgiou1,2, Emmanuelle Mathieu d'Argent3, Patrick Van Dreden4, Ismail Elalamy1,2, Grigorios Gerotziafas1,2
1Cancer Biology and Therapeutics, INSERM U938, Institut Universitaire de Cancerologie (IUC), Universite Pierre et Marie Curie (UPMC), Paris, France, 2Department of Haematology, Tenon University Hospital, Paris, France, 3Department of Obstetrics and Gynecology, Tenon University Hospital, Paris, France, 4Clinical Research Department, Stago, Gennevilliers, Paris, France

P21
The Method Of Obtaining Virus Safety Of Factor Viii Coagulation
Natalia Shurko1, Taras Danysh1, Vasyl Novak1
1Institute of Blood Pathology and Transfusion Medicine NAMS , Lviv, , 2Institute of Blood Pathology and Transfusion Medicine NAMS, Lviv, , 3Institute of Blood Pathology and Transfusion Medicine NAMS, Lviv,

P22
An Ambiguous Choice Of Anticoagulant In Atrial Fibrillation With Factor X Deficiency
Jian Liang Tan1, Kheng Joe Lau2, Anshul Fnu1, Arezoo Ghaneie1
1Crozer-Chester Medical Center, Upland, PA, United States, 2John H. Stroger Jr. Hospital of Cook County, Chicago, IL, United States

P23
Is A Fviii Product With Improved Storage Flexibility And &Ldquo;Portability Features&Rdquo; Of Interest To Us Patients With Hemophilia A And Their Caregivers? A Conjoint Analysis.
Yan Wang1, Neeraj N. Iyer2, Jennifer Kirschenbaum1, Alison Currie1, Natalia Holot2, Juliana Setyawan2
1WG Group, New York, NY, United States, 2Novo Nordisk, Inc., Plainsboro, NJ, United States

P24
Sekisui Aptt Results Are Equivalent With Diagnostica Stago Sta-C.K. Prest Results
Betul Yilmaz1, Yaman Sevim1, Larry Smith2, Gabriella Lakos2
1Bartin Public Hospital, Bartin, Turkey, 2Abbott Diagnostic Division - Hematology, Santa Clara, CA, United States

11:00 - 12:00 PMGrand 8-9
Short Talks: Vascular Wall Biology

Chair(s): A Koneti Rao and Clay T. Cohen
11:00
Extracellular Rna Is A Novel Activator Of Tissue Factor Under Hypoxic Stress Condition
Saumya Bhagat1, Indranil Biswas1, Ankit Tripathi1, Sarada Surya Kumari1, Sanjeev Puri2, Gausal Azam Khan1
1Defence Institute of Physiology and Allied Sciences, DRDO, New Delhi, India, 2University Institute of Engineering and Technology, Panjab University, Chandigarh, India

11:15
A New Human Endothelial Cell-Based Model Of Intrinsic Coagulation
Clay T Cohen1,2, Nancy A Turner3, Joel L Moake3
1Department of Pediatrics, Section of Hematology-Oncology, Texas Children’s Cancer and Hematology Centers, Houston, TX, United States, 2Baylor College of Medicine, Houston, TX, United States, 3Rice University, Department of Bioengineering, Houston, TX, United States

11:30
The Role Of Thrombogenesis In Atrial Fibrillation Patients Compared To The Normal Population
Sallu Jabati1, Abigail Otto1, Jeffrey Liles1, Debra Hoppensteadt1, Jack Bontekoe1, Trung Phan1, Amanda Walborn1, Mushabbar Syed2, Jawed Fareed1
1Department of Pathology, Loyola University Medical Center, Maywood, IL, United States, 2Department of Cardiology, Loyola University Medical Center, Maywood, IL, United States

11:45
Efficient Alternative Complement Pathway Regulation Decreases C3A And C5A Generation In Human Cerebral Vs. Renal Microvascular Endothelial Cells
Sarah E. Sartain1, Nancy A. Turner2, Joel L. Moake 2
1Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston , TX, United States, 2Department of Bioengineering, Rice University, Houston , TX, United States

11:00 - 12:00 PMGrand 10
Short Talks: Risk

Chair(s): James Douketis and Camila Masias
11:00
A New Risk Assessment Model For Vte Prediction In Pancreatic Cancer
Anton Ilich1, Elena Campello2, Michael Henderson1, Raj Kasthuri1, Denis Noubouossie1, Mark Piegore1, Rafal Pawlinski1, Feng-Chang Lin1, Nigel Mackman1, Paolo Simioni2, Nigel Key1
1University of North Carolina, Chapel Hill, NC, United States, 2University of Padova, Padova, Italy

11:15
Prediction Of Relapse Based On Remission Adamts13 Activity In Patients With Immune-Mediated Thrombotic Thrombocytopenic Purpura
Camila Masias1, Clare Stevens1, Shangbin Yang1, Michael McGookey1, Lauren Jay1, Haiwa Wu2, James George1, Spero /R Cataland
1The Ohio State University College of Medicine, Columbus, OH, United States, 2University of Oklahoma College of Medicine, Oklahoma City, OK, United States

11:30
Prospective Validation Of The Hit Expert Probability (Hep) Score For The Diagnosis Of Heparin-Induced Thrombocytopenia
Allyson M. Pishko1, Daniel S. Lefler1, Sara Fardin2, Koosha Paydary3, Gowthami M. Arepally4, Mark A. Crowther5, Lawrence Rice6, Rolando Vega1, Douglas B. Cines1,7, Adam Cuker1,7
1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States, 2Department of Medicine, Jersey Shore University Medical Center, Neptune, NJ, United States, 3Department of Internal Medicine, John H. Stroger Jr. Hospital of Cook County, Chicago, IL, United States, 4Department of Medicine, Duke University, Durham, NC, United States, 5Department of Medicine, McMaster University, Hamilton, Canada, 6Department of Medicine, Weill Cornell Medical College, Houston, TX, United States, 7Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Philadelphia, PA, United States

11:45
Validation Of Institutional Clinical Care Guidelines In Predicting Risk Of Hospital-Acquired Venous Thromboembolism In An Academic Children&Rsquo;S Hospital
Emily Southard, Allaura Cox, Bryce Clark, Beth Wathen, Kenneth Hammett, Joanne Hilden, Brian Branchford
Children's Hospital Colorado, Aurora, CO, United States

11:00 - 12:00 PMGrand 12
Short Talks: Animal Models

Chair(s): Shannon Carpenter and Alisa Wolberg
11:00
Subclinical Hemorrhage Induces Cytokine Changes That May Contribute To Inhibitor Development In A Hemophilia Mice Model
Yasmina L Abajas1, Baolai Hua2, Chengwen Li1, Junjiang Sun1
1University of North Carolina, Chapel Hill, NC, United States, 2Northern Jiangsu People's Hospital, Yangzhou, China

11:15
Co-Administration Of Factor Viii With Intravenous Immunoglobulin Reduces Immune Response To Factor Viii In Hemophilia A Mice
Sajjad Afraz1, Jianping Wen1, Anthony K.C. Chan1, Gonzalo Hortelano2
1McMaster University, Hamilton, ON, Canada, 2Nazarbayev University, Astana, Kazakhstan

11:30
A Unique Model Of Type 1 And Type 3 Vwd Established In A Vwf Knock Out Rat Developed Via Crispr/Cas9
Jessica Garcia1,2, Veronica Flood1,2, Scot Fahs2, Jeremy Mattson2, Robert Montgomery2
1Department of Pediatrics, Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, United States, 2Blood Research Institute, BloodCenter of Wisconsin, Milwaukee, WI, United States

11:45
Murine Studies To Test The Efficacy Of Platelet Transfusions In The Management Of Platelet Function Disorders
Robert H Lee1, Raymond Piatt1, David S Paul1, Wolfgang Bergmeier1,2
1UNC McAllister Heart Institute, Chapel Hill, NC, United States, 2UNC Department of Biochemistry and Biophysics, Chapel Hill, NC, United States

11:00 - 12:00 PMGrand 13
Short Talks: Hemostasis - Clinical/Translational I

Chair(s): Jim Munn and Homa K. Ahmadzia
11:00
Prediction Of Peripartum Blood Transfusion
Homa K. Ahmadzia1, Andra H. James2, Madeline M. Rice3, Richard L. Amdur1
1George Washington University Medical Faculty Associates, Washington , DC, United States, 2Duke University, Durham, NC, United States, 3George Washington University Biostatistics Center, Rockville, MD, United States

11:15
Thrombin Generation And Rotational Thromboelastometry In Obese And Non-Obese Adolescent Females Initiating Combined Oral Contraceptives
Fareeda W. Haamid1, 2, Amanda P. Waller3, Brittny E. Manos3, Sarah H. O'Brien1,2,3, Andrea E. Bonny1,2,3, Bryce A. Kerlin1,2,3
1Nationwide Children's Hospital, Columbus, OH, United States, 2The Ohio State University College of Medicine, Columbus, OH, United States, 3The Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States

11:30
Plasminogen Activator Inhibitor-1 Deficiency During Pregnancy And Postpartum
Amanda D. Kaveney, Joshua A. Kra, Ambarina Faiz, Claire Philipp
Rutgers Univeristy-Robert Wood Johnson Medical School, New Brunswick, NJ, United States

11:45
Nephrotic Syndrome-Associated Hypercoagulopathy Is Alleviated By Steroid Therapy
Bryce A. Kerlin1-3, Amanda P. Waller1, Katelyn J. Wolfgang1, Melinda A. Chanley1, Shipra Agrawal1,2, William E. Smoyer1,2,4
1Center for Clinical & Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, United States, 2Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, United States, 3Division of Hematology/Oncology/BMT, Nationwide Children’s Hospital, Columbus, OH, United States, 4Division of Nephrology, Nationwide Children’s Hospital, Columbus, OH, United States

12:00 - 2:00 PMGrand 1-2
Satellite Symposium Lunch- Bioverativ

12:00 - 2:00 PMGrand 3-4
Satellite Symposium Lunch- CSL Behring

2:00 - 3:30 PMGrand 5-7
Regulatory Mechanisms in Coagulation - New Insights

Chair(s): Shannon Meeks and Alan Mast
2:00
New Insights Into Tfpi And Protein S In The Regulation Of Coagulation
Alan Mast
Blood Center of Wisconsin

2:30
Anti-Inflammatory Signaling Mechanism Of Antithrombin
Ray Rezaie
Oklahoma Medical Research Foundation

3:00
Anti-Thrombotic Potential Of The Contact Activation Pathway
Alvin Schmaier
CWRU School of Medicine

2:00 - 3:30 PMGrand 8-9
Controversies in Platelet Disorders

Chair(s): Peter Kouides and Michele Lambert
2:00
Using Genomics And Proteomics To Dissect Platelet Disorders
Jorge DiPaola
University of Colorado School of Medicine

2:30
Are We Underdiagnosing Storage Pool Disorders?
Michele Lambert
Children's Hospital of Philadelphia

3:00
Transcription Factor Runx1 - From Platelet Dysfunction To Cardiovascular Disease
A. Koneti Rao
Lewis Katz School of Medicine at Temple University

2:00 - 3:30 PMGrand 10-11
Applications and Interpretations in Bleeding and Clotting Disorders

Chair(s): Donna Castellone and Kristi Smock
2:00
The Coagulation Laboratory And The Transfusion Service: An Ever-Changing Partnership
Richard Francis
Columbia University Medical Center

2:30
Evaluation Of Complex Coagulation Cases: Case-Based Illustrations Of Important Issues
Kristi Smock
University of Utah Health Sciences Center and ARUP Laboratories

3:00
Important Considerations For Coagulation Tests On Children And Neonates
Cindy Neunert
Columbia University Medical Center

3:30 - 4:15 PMPacific Ballroom
Poster Session/Exhibits

P27
Clinical Manifestations Of Vascular Ehlers-Danlos Syndrome &Ndash; Single Institution Experience.
Kamila I. Cisak, David R. Deyle, Rajiv K. Pruthi
Mayo Clinic, Rochester, MN, United States

P28
Evaluation Of The Immature Platelet Fraction For Distinguishing Inherited Macrothrombocytopenia From Immune Thromboctyopenia In Children
Modupe Adetunji1, Abinaya Arulselvan2, Alicia McDonnell2, Michele Lambert2
1Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States, 2Children's Hospital of Philadelphia, Philadelphia, PA, United States

P29
Consultation For Thrombocytopenia In Hospitalized Patients
Michael Boxer
Arizona Oncology, Tucson, AZ, United States

P30
Evaluation Of Relationships Between Platelet Dense Granule Deficiency, Impaired Aggregation Responses, And Impaired Dense Granule Adenosine Triphosphate Release
Justin G. Brunet1, Janaki K. Iyer1, Matthew S. Badin1, Lukas Graf2, Karen A. Moffat3,4, Ernie Spitzer1, Marnie Timleck1, Catherine P. M. Hayward1,3,4
1Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada, 2Centre for Laboratory Medicine and Hemophilia and Hemostasis Centre, St. Gallen, Switzerland, 3Department of Medicine, McMaster University, Hamilton, ON, Canada, 4Hamilton Regional Laboratory Medicine Program, Hamilton, ON, Canada

P31
Runx1-Related Familial Platelet Disorder With Predisposition To Acute Myeloid Leukemia (Fpd/Aml) Presenting With Bleeding And Normal Platelet Count: The Importance Of Recognizing The Platelet Dysfunction As Part Of The Phenotype
Stefanie N Dugan , Mia J Sullivan, Mitchell G Springer, Valerie Trapp-Stamborski, Jamie McCreery, Ruchika Sharma, Kenneth D Friedman, Brian R Curtis, Lijun Wang, Shawn M Jobe, Juliana Perez Botero
BloodCenter of Wisconsin, Milwaukee, WI, United States

P34
Platelet Transcriptomic Signatures In Myeloproliferative Neoplasms
Anandi Krishnan1, Cecelia Perkins2, Jason Gotlib2, James Zehnder1,2
1Department of Pathology, Stanford University, Stanford, CA, United States, 2Division of Hematology, Department of Medicine, Stanford University, Stanford, CA, United States

P35
Fostamatinib, A Spleen Tyrosine Kinase Inhibitor, Is Active In The Treatment Of Warm Antibody Autoimmune Hemolytic Anemia: Results Of The Soar Phase 2, Multicenter, Open-Label Study
David J Kuter1, Donald Arnold2, Richy Agajanian3, Michael Choi4, Alan Lichtin5, Kerry A Rogers6, Michael A Boxer7, Catherine Broome8, Joshua J Field9, Irina Murakhovskaya10, Ann M Lowe11, Hany Zayed12, Sandra Tong12, Anne-Marie Duliege12
1Massachusetts General Hospital, Boston, MA, United States, 2Michael G. DeGroote School of Medicine, Department of Medicine, McMaster, Hamilton, ON, Canada, 3The Oncology Institute of Hope and Innovation, Downey, CA, United States, 4University of California San Diego, San Diego, CA, United States, 5Hematologic Malignancies and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, United States, 6Division of Hematology, The Ohio State University, Columbus, OH, United States, 7Arizona Oncology, Tucson, AZ, United States, 8Division of Hematology, Georgetown University, Washington, DC, United States, 9Blood Center of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, United States, 10Montefiore Medical Center, Bronx, NY, United States, 11Rigel Pharmaceuticals Inc., West Lake Hills, TX, United States, 12Rigel Pharmaceuticals Inc., South San Francisco, CA, United States

P36
Rituximab Use In Elderly Patients Newly Diagnosed With Primary Immune Thrombocytopenia (Itp): Incidence, Patient Characteristics, And Treatment Patterns
Shuling Li1, Julia Molony1, Anne Sexter1, Karynsa Cetin2, Ivy Altomare3, Jeffrey Wasser4
1Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN, United States, 2Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, United States, 3Department of Medicine, Duke University Medical Center, Durham, NC, United States, 4Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine, Farmington, CT, United States

P37
Splenectomy In Elderly Patients Newly Diagnosed Wtih Primary Immune Thrombocytopenia (Itp): Incidence, Patient Characteristics, And Outcome
Shuling Li,1, Anne Sexter1, Julia Molony1, Karynsa Cetin 2, Jeffrey S. Wasser3, Ivy Altomare4
1Chronic Disease Research Group, Minneapolis Medical Research Foundation, Minneapolis, MN, United States, 2Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, United States, 3Carole and Ray Neag Comprehensive Cancer Center, University of Connecticut School of Medicine, Farmington, CT, United States, 4Department of Medicine, Duke University Medical Center, Durham, NC, United States

P38
Real-World Patterns Of Romiplostim Treatment In Adults With Primary Immune Thrombocytopenia In The United States
Leah McGrath1, Karynsa Cetin2, Robert Overman1, Diane Reams1, Anjali Sharma2, Ivy Altomare3, M. Alan Brookhart1, Jeffrey Wasser4
1NoviSci, LLC, Durham, NC, United States, 2Amgen Inc., Thousand Oaks, CA, United States, 3Duke University Medical Center, Durham, NC, United States, 4UConn Health, University of Connecticut , Farmington, CT, United States

P39
Improving Laboratory Testing For Heparin Induced Thrombocytopenia
Ishac Nazy, Jane C. Moore, Donald M. Arnold
McMaster University , Hamilton, ON, Canada

P40
Effect Of Therapeutic Levels Of Heparin On The Hit-Pf4 Elisa Antibody Assay
Preston M Parker1, Jay S Raval2, Nathan D Montgomery2, Marian A Rollins-Raval2
1UNC Healthcare, Chapel Hill, NC, United States, 2University of North Carolina, Chapel Hill, NC, United States

P42
Predictors Of Hemorrhage Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Bethany T Samuelson Bannow1, Kelsey K Baker2, Barbara A Konkle1,3, David A Garcia1, Fred R Appelbaum4,5, Brenda M Sandmaier4,5
1University of Washington Medical Center, Division of Hematology, Seattle, WA, United States, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 3Bloodworks Northwest, Seattle, WA, United States, 4Fred Hutch Cancer Research Center, Clinical Research Division, Seattle, WA, United States, 5University of Washington Medical Center, Division of Oncology, Seattle, WA, United States

P44
Bay 94-9027: A Long-Acting, Site-Specifically Pegylated, B-Domain&Ndash;Deleted Recombinant Factor Viii Product Of High And Consistent Purity For Prolonged Protection In Patients With Hemophilia A
Paul Whetstone, Cary Matanguihan, Nelly Tsvetkova, Nicole Samuels, John Teare
Bayer, Berkeley, CA, United States

P45
The Epidemiology And Management Of Platelet Refractoriness At A Comprehensive Cancer Center
Wei Yang1,2, Ashok Tholpady1, Kelly Casteel1, Cristhiam Rojas-Hernandez1
1University of Texas MD Anderson Cancer Center, Houston, TX, United States, 2University of Texas Health Science Center at Houston, Houston, TX, United States

P46
Bleeding Risk With Heparin Therapy In Critically Ill Patients: Can Thromboelastography Assist?
Oksana Volod, George Chaux, Xiaotian Qin, Nari Kim, Sylvia Martin-Stone
Cedars-Sinai Medical Center, Los Angeles, CA, United States

P48
A Case Of Acquired Factor Viii Deficiency In An Elderly Female
Cynthia Woods
Penn State Health, Hershey, PA, United States

P156
Differential Sensitivity Of Von Willebrand Factor Activity Assays To Reduced Vwf Molecular Weight Forms: A Large International Cross-Laboratory Study.
Piet Meijer1, Emmanuel J Favaloro2, Roslyn Bonar3, Martine Hollestelle1, Ian Jennings4, Soma Mohammed2, Timothy Woods4, Muriel Meiring5
1ECAT Foundation, Voorschoten, Netherlands, 2Westmead Hospital, Sydney, Australia, 3Royal College of Pathology of Australasia Quality Assurance Program , Sydney, Australia, 4UKNEQAS Blood Coagulation, Sheffield, United Kingdom, 5University of the Free State, Bloemfontein, , South Africa

4:15 - 5:45 PMGrand 5-7
Thrombosis in Challenging Patient Populations (with case presentations)

Chair(s): Lynn Oertel and Kavita Patel
4:15
Obesity, Renal Failure, Hit: Which Anticoagulant To Use?
Mark Crowther
McMaster University

4:45
Patients With Atrial Fibrillation And Bleeding Risk: Does Reversal Agent Influence Anticoagulant Choice?
Renato Lopes
Duke Clinical Research Institute

5:15
Thrombolysis And Thrombectomy In Pediatrics
Marilyn Manco Johnson
University of Colorado Anschutz Medical Campus

4:15 - 5:45 PMGrand 8-9
The Past, Present and Future of von Willebrand Disease

Chair(s): Veronica Flood and Ken Friedman
4:15
What We Have Learned And Hope To Learn From Databases
Robert Sidonio
Emory University and Children's Healthcare of Atlanta

4:45
New Lab Testing, Utilization And Practical Aspects
Jonathan Roberts
Bleeding and Clotting Disorders Institute

5:15
Overview And Controversies In Low Vwf And Mild Vwd
Michelle Lavin
1. Irish Centre for Vascular Biology, Royal College of Physicians of Ireland and 2. National Coagulation Centre, St. James's Hospital, Dublin

4:15 - 5:45 PMGrand 10-11
Platelet Biogenesis and Signaling

Chair(s): A. Koneti Rao and Kellie Machlus
4:15
Novel Mechanisms Of Proplatelet Initiation
Kellie Machlus
Brigham and Women's Hospital

4:45
Novel Regulators Of Gpvi Signaling In Platelets
Satya Kunapuli
Lewis Katz School of Medicine

5:15
Cellular Basis Of Secretion
Brian Storrie
University of Arkansas for Medical Sciences

5:45 - 6:30 PMPacific Ballroom
Opening Reception and Poster Session/Exhibits

P49
A Predictive Score For Thrombosis Associated With Breast, Colorectal, Lung, Or Ovarian Cancer: The Prospective Compass&Ndash;Cancer‐Associated Thrombosis Study
Grigorios Gerotziafas1,2, Ali Taher3, Hikmat Abdel-Razeq4, Essam AboElnazar5, Alex Spyropoulos6, Salem El Shemmari7, Annette Larsen1, Ismail Elalamy1,2
1Cancer Biology and Therapeutics, INSERM U938, Institut Universitaire de Cancérologie (IUC), Faculté de Médecine Pierre et Marie Curie, Université Pierre et Marie Curie (UPMC), Paris, France, 2Service d'Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Paris, France, 3Department of Internal Medicine, Division of Hematology/Oncology, American University of Beirut, Beirut, Lebanon, 4Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan, 5Surgery Department, Umm Al‐Qura University, Mecca, Saudi Arabia, 6Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Hofstra Northwell School of Medicine, Northwell Health System, Manhasset, New York, NY, United States, 7Department of Medical Oncology, Kuwait Cancer Control Center, Kuwait City, Kuwait

P50
Predictors Of Venous Thromboembolism Among Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Bethany T Samuelson Bannow1, Kelsey K Baker2, Barbara A Konkle1,3, David A Garcia1, Fred R Appelbaum2,4, Brenda M Sandmaier2,4
1University of Washington Medical Center, Division of Hematology, Seattle, WA, United States, 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States, 3Bloodworks Northwest, Seattle, WA, United States, 4University of Washington Medical Center, Division of Oncology, Seattle, WA, United States

P51
Risk For Venous Thromboembolism In The Continuum Of Care Among Patients Hospitalized For Acute Medical Illnesses In The Us
Alpesh Amin1, W. Richey Neuman2, Melissa Lingohr-Smith3, Brandy Menges3, Jay Lin3
1Univeristy of California, Irvine, Irvine, CA, United States, 2Portolola Pharmaceuticals, South San Francisco, CA, United States, 3Novosys Health, Green Brook, NJ, United States

P52
Patient Safety Indicator-12 Rarely Identifies Problems With Quality Of Care In Perioperative Venous Thromboembolism
Lisa Baumann Kreuziger1,2,3, Benjamin Jung3, Lori Sommervold3, Siddhartha Singh2,3
1BloodCenter of Wisconsin, Milwaukee, WI, United States, 2Medical College of Wisconsin, Milwaukee, WI, United States, 3Froedtert Hospital, Milwaukee, WI, United States

P54
Evaluation Of Antithrombin-Iii Concentrate Administration For Suspected Heparin Resistance At An Academic Medical Center
Kathryn Dane1, Satish Shanbhag2, Michael Streiff2, Glenn Whitman3, Jessica Crow1
1Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States, 2Department of Medicine, The Johns Hopkins Hospital, Baltimore, MD, United States, 3Department of Cardiac Surgery, The Johns Hopkins Hospital, Baltimore, MD, United States

P55
Warfarin Anticoagulation Variability, Testing, And Dose-Adjustment Frequency Is Reduced In Clinical Practice After Switch From Prothrombin Time Based International Normalized Ratio (Inr) To Fiix-Prothrombin Time Based Normalized Ratio (Fiix-Nr).
Brynja R. Gudmundsdottir1, Pall T. Onundarson1,2
1Landspitali National University Hospital, Reykjavik, Iceland, 2Faculty of Medicine, University of Iceland, Reykjavik, Iceland

P56
Anti-Xa Monitoring Of Therapeutic Enoxaparin In Patients Weighing At Least 90 Kilograms
Erik Henricksen1, Lindsey Federle2,3, Molly Droege2,3, Maria Guido2,3
1University of California, San Francisco, San Francisco, CA, United States, 2UCHealth - University of Cincinnati Medical Center, Cincinnati, OH, United States, 3University of Cincinnati College of Pharmacy, Cincinnati, OH, United States

P57
Usp Potency Adjusted Bovine Mucosal Heparins Are Comparable To Porcine Mucosal Heparin At Equivalent Levels
Walter Jeske, Ahmed Kouta, Ambar Farooqui, Fakiha Siddiqui, Rajan Laddu, Debra Hoppensteadt, Omer Iqbal, Paula Maia, Jawed Fareed
Loyola University Chicago Health Sciences Division, Maywood, IL, United States

P58
Purified Porcine And Bovine Heparin Preparations With Enhanced Biological Activities
Ahmed Kouta1, Richard Yin2, Fakiha Siddiqui1, Ambar Farooqui1, Rajan Laddu1, Walter Jeske1, Debra Hoppensteadt1, Zafar Siddiqui1, Jawed Fareed1
1Loyola University Chicago Health Sciences Division, Maywood, IL, United States, 2Yino Pharma, Chongqing, , China

P59
Enoxaparin Discharge Education For Pediatric Inpatients: A Prospective Pilot Study
Jennifer R Lissick1, Monica D Premsukh2
1Children's Minnesota, Minneapolis, MN, United States, 2Children's Minnesota, St. Paul, MN, United States

P61
Athn 4: Transition Of Care For Patients With Venous Thromboembolism (Vte)
Maura Malone1, Maria M DeSancho2, James E Munn3, Julie Jaffray4, Ellen G McCarthy5, Dunlei Cheng5, Crystal Watson5, Madhvi Rajpurkar6
1Dartmouth-Hitchcock Hemophilia Center, Lebanon, NH, United States, 2New York Presbyterian, Weill Cornell Medicine, New York, NY, United States, 3Michigan Medicine Hemophilia & Coagulation Disorders Program, University of Michigan, Ann Arbor, MI, United States, 4Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, United States, 5American Thrombosis and Hemostasis Network (ATHN), Rochester, NY, United States, 6Children’s Hospital of Michigan, Wayne State University, Detroit, MI, United States

P62
Pull & Pray: Outcomes With A No-Anticoagulation Approach To Picc Line Associated Thrombosis.
Dylan A Mart, Jeffrey Y Bien, Ashray Maniar, Joseph J Shatzel, Thomas G Deloughery
Oregon Health & Science University, Portland, OR, United States

P63
Evaluation Of Doac Failure In Cancer Patients On Active Treatment
Kathleen O'Neill1,2, Betty Rowe1,2, Huong L Truong1, Audrea Szabatura1, Houry Leblebjian1, Christy S Harris1, Jean M Connors1,2
1Brigham and Women's Hospital, Boston, MA, United States, 2Dana Farber Cancer Institute, Boston, MA, United States

P64
Direct Oral Anticoagulants In Post-Operative Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery
Ammie Patel1, Alejandro Rodriguez1, Greenberg Patricia1, Michelle Kohute1, Rachael Durie1, 2
1Jersey Shore University Medical Center, Neptune, NJ, United States, 2Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States

P65
Bone Mineral Density In Pediatric Patients Receiving Chronic Anticoagulation
Lauren B. Fogelgren1, Jennifer Y. Pecot1, Megan C. Brown1,2, Briana C. Patterson1,2, En Cheng3, Kavita N. Patel1,2
1Aflac Cancer and Blood Disorders Center, Atlanta, GA, United States, 2Children’s Healthcare of Atlanta, Atlanta, GA, United States, 3Emory University School of Medicine, Atlanta, GA, United States

P66
Exploring The Rationale And Outcomes Of Vena Cava Filter Placement In Patients With Malignancy
Prashant Raghavendran, Ming Y. Lim
Medical University of South Carolina, Charleston, SC, United States

P67
Sustained Anticoagulant Effect And High Inter-Individual Variability Among Patients In Treatment With Rivaroxaban Demonstrated By Thrombin Generation And Thromboelastometry
Stella Salta1,2, Patrick Van Dreden3, Loula Papageorgiou1,2, Jawed Fareed4, Ismail Elalmy1,2, Grigorios Gerotziafas1,2
1Cancer Biology and Therapeutics, INSERM U938, Institut Universitaire de Cancerologie (IUC), Universite Pierre et Marie Curie (UPMC), Paris, France, 2Department of haematology, Tenon University Hospital, Paris, France, 3Stago, Gennevilliers, Paris, France, 4Loyola University, Chicago, IL, United States

P68
Novel Mechanism And Anti-Thrombotic Therapy: Role Of The Β3 Integrin Plexin-Semaphorin-Integrin (Psi) Domain In Blood Coagulation
Tyler W. Stratton1-3, Guangheng Zhu1,2, Yiming Wang1,2, Pingguo Chen1,2,4, Miguel A. D. Neves1,2, Reid C. Gallant1-3, Peter A. A. Norris1-4, John Freedman1-3,5,6, Heyu Ni1-6
1Department of Laboratory Medicine, Keenan Research Centre for Biomedical Science, St. Michael's Hospital, Toronto, ON, Canada, 2Toronto Platelet Immunobiology Group, Toronto, ON, Canada, 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, 4Canadian Blood Services, Toronto, ON, Canada, 5Department of Medicine, University of Toronto, Toronto, ON, Canada, 6Department of Physiology, University of Toronto, Toronto, ON, Canada

P69
Effect Of Direct Oral Anticoagulants On Fibrinogen Induced Pseudoparaproteinemia
Jennifer Teichman1, Danielle Hammond2, Stephanie Fenech3, Michelle Sholzberg1,3,4
1University of Toronto Department of Medicine, Toronto, ON, Canada, 2Queen's University, Division of Hematology, Kingston, ON, Canada, 3St. Michael's Hospital, Toronto, ON, Canada, 4Li Ka Shing Knowledge Institute, Toronto, ON, Canada

P70
Direct Thrombin Inhibitor For Anticoagulation In An Infant With Persistent Thrombocytopenia And Platelet Refractoriness On Extracorporeal Membrane Oxygenation Life Support- A Case Report
Dena Wideman1, Mukta Sharma1,2
1Children's Mercy, Kansas city, MO, United States, 2University of Missouri Kansas City, kansas city, MO, United States

P71
Perspectives On Prophylactic Factor Replacement From Adult Patients With Moderate And Severe Hemophilia
Jessica Petrucci1, Georgina Floros1, Avery Longmore1,2, Jerome Teitel1,2, Michelle Sholzberg1,2,3
1St. Michael's Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Li Ka Shing Knowledge Institute, Toronto, ON, Canada

P72
Impact And Management Of Drug-Drug Interactions Between Apixaban Or Rivaroxaban And Systemic Azole Antifungal Therapy.
Allison Stilwell, Svetlana Goldman, Surabhi Palkimas
University of Virginia Health System, Charlottesville , VA, United States

6:30 - 8:30 PMGrand 1-2
Satellite Symposia Dinner - Shire



Friday, March 9, 2018


8:00 - 9:15 AMGrand 5-7
Antiphospholipid Syndrome (APLS) and its challenges, from the patient to the laboratory

Chair(s): Richard Marlar and Julie Jaffray
8:00
A Hematologist'S Perspective On Apls
Morey Blinder
Washington University School of Medicine

8:25
An Obstetrician'S Perspective On Apls-Related Pregnancy Complications
D. Ware Branch
University of Utah, Salt Lake City , UT, United States

8:50
Challenges In Laboratory Testing Of Apls
Dorothy Adcock
Esoterix Coagulation

8:00 - 9:15 AMGrand 8-9
Hot Topics: Hemophilia Gene Therapy in 2018 and Beyond

Chair(s): Michael Paidas and Lindsey George
8:00
Pre-Clinical Challenges, Barriers And Strategies
Chris Doering
Emory University School of Medicine

8:25
Clinical Update
Lindsey George
The Children's Hospital of Philadelphia

8:50
Coagulation Disorders: Fishing For New Therapeutics Using Genome Editing
Jordan Shavit
University of Michigan

8:00 - 9:15 AMGrand 10-11
MicroRNAs and Microparticles in Thrombosis and Cancer

Chair(s): Marvin Neiman and Donna Woulfe
8:00
Platelet Microrna
Jesse Rowley
University of Utah School of Medicine

8:25
Tmem16F-Dependent Platelet Microparticles Contribute To Thrombosis
Donna Woulfe
University of Delaware

8:50
The Role Of Platelet Microparticles Microrna In Tumor Suppression
Lawrence Goldfinger
Lewis Katz School of Medicine

9:15 - 10:00 AMPacific Ballroom
Poster Session and Exhibits

P74
Structure And Function Of Anticoagulation Clinics In The United States: An Ac Forum Membership Survey
Geoffrey Barnes1, Eva Kline-Rogers1, Christopher Graves1, Eric Puroll1, Kevin Townsend2, Ellen McMahon2, Terri Craig2, James Froehlich1
1University of Michigan, Ann Arbor, MI, United States, 2Pfizer, US Medical Affairs, New York, NY, United States

P75
Prevalence And Correlates Of Bleeding And Emotional Harms In A National Us Sample Of Patients With Venous Thromboembolism: A Cross-Sectional Structural Equation Model.
Michael Feehan1,2,3, Michael Walsh4, Heather Van Duker4, Jon Godin4, Mark A. Munger1,5, Ryan P. Fleming6, Stacey A. Johnson6,7, Margaret M. DeAngelis3, Daniel M. Witt1,6
1University of Utah College of Pharmacy, Salt Lake City, UT, United States, 2Kantar Millward Brown, San Francisco, CA, United States, 3Moran Eye Center, University of Utah School of Medicine, Salt Lake City, UT, United States, 4Hall and Partners, New York, NY, United States, 5Department of Internal Medicine University of Utah School of Medicine, Salt Lake City, UT, United States, 6University of Utah Health, Thrombosis Service, Salt lake City, UT, United States, 7Department of General Internal Medicine, University of Utah Medical School, Salt Lake City, UT, United States

P76
Influence Of Abcb1 2677G>T Single Nucleotide Polymorphism On Warfarin Maintenance Therapy Among Patients With Prosthetic Heart Valve.
Gopisankar M G, M. Hemachandren, A. Surendiran
JIPMER, Puducherry, India

P77
Establishment Of One-Of-A-Kind Group Patient Education Class For Direct Oral Anticoagulants Follow-Up
Sweta Patel1,2, Mary Katherine Cheeley1, Mikhail Akbashev1,3, Smitha John1,4
1Grady Health System, Atlanta, GA, United States, 2Mercer University College of Pharmacy, Atlanta, GA, United States, 3Emory University School of Medicine, Atlanta, GA, United States, 4Morehouse School of Medicine, Atlanta, GA, United States

P78
Assessment Of The Efficiency And Effectiveness Of The Anticoagulation-Related Discharge Communication
Kelly M Rudd1, Darren Triller2, Anne Myrka3, Matthew Jones1, Jennifer Mondore1, Robin Lopez1, Marcy Canary1
1Bassett Medical Center, Cooperstown, NY, United States, 2WellScriptEd Consulting, Inc., Delmar, NY, United States, 3IPRO, Albany, NY, United States

P79
Does Warfarin Really Cause Acute Kidney Injury? A Retrospective Study
Hugh Traquair, Noel Chan, Marlene Robinson, Sam Schulman, Siavash Piran
Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada

P80
Anticoagulation Management In A Hemophilia A Patient
Katie Xu, H. Paige Erdeljac, Stephanie Yager, Aaron Dush, Tzu-Fei Wang
The Arthur G James Cancer Hospital and Richard J Solove Research Institute at The Ohio State University, Columbus , OH, United States

P81
Assessment Of Current Testing Processes For Factor Viii/Ix Assays&Mdash;A Survey Of Us Coagulation Laboratories
Dorothy Adcock1, Richard Marlar2, Natalia Holot3, David Cooper3
1Colorado Coagulation, Laboratory Corporation of America Holdings, Englewood, CO, United States, 2Department of Pathology, University of New Mexico Health Sciences Center, Albuquerque, NM, United States, 3Novo Nordisk Inc, Plainsboro, NJ, United States

P82
Oral Contraceptive-Induced Risk Of Thrombosis In Premenopausal Women And Opportunities For Protein S Therapy
Sadaf Afreen3, Heather Cancienne1, Vijaya Pilli1, Rima Chattopadhyay1, Arani Datta2, Eric Lazartigues1, Rinku Majumder
1Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, New Orleans, LA, United States, 2Department of Pharmacology and Experimental Therapeutics, Louisiana State University Health Sciences Center, New Orleans, LA, United States, 3University of Leicester, Leicester, United Kingdom

P83
Post-Marketing Safety Studies Of Recombinant Porcine Factor Viii In The United States And European Union
Roberto Crea1, Oliver Mauric1, Jui-Fu Huang2
1Shire, Vienna, Austria, 2Shire, Cambridge, MA, United States

P84
Feiba Go Study: Real-World Bleeding Frequency In Inhibitor Patients On Prophylaxis With Activated Prothrombin Complex Concentrates
Carmen Escuriola Ettingshausen1, Jerzy Windyga2, Pal A. Holme3, Cedric Hermans4, Claude Negrier5, Ana R. Cid6, Savita Rangarajan7, Angiola Rocino8, Gretchen R. Chiu9, Roberto Crea10
1HZRM, Haemophilia Centre Rhine-Main, Frankfurt-Möerfelden, Germany, 2Institute of Hematology and Transfusion Medicine, Warsaw, Poland, 3Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway, 4Saint-Luc University Hospital, Brussels, Belgium, 5Louis Pradel Cardiology Hospital, University Claude Bernard, Lyon, France, 6Unidad Hemostasia y Trombosis, Hospital Universitario y Politécnico La Fe, València, Spain, 7Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom, 8Haemophilia & Thrombosis Centre, Ascalesi Hospital, Naples, Italy, 9Shire, Lexington, United States, 10Shire, Vienna, Austria

P85
Heat Inactivation Of Extended Half-Life Factor Viii Concentrates
Kara A Fylling, Julie I Tange, Dong Chen , Rajiv K Pruthi
Special Coagulation Laboratory, Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, United States

P86
Inhibition Of Thrombin And Its Generation By Recombinant Thrombomodulin And Activated Protein C In Whole Blood And Plasma Based Systems
Debra Hoppensteadt1, Jawed Fareed1, Walter Jeske1, Paula Maia1, Kosuke Tanaka2, Kazuhisa Tsuruta2
1Loyola University Chicago, Maywood, IL, United States, 2Asahi Kasei Pharma America, Waltham, MA, United States

P87
Anticoagulant Actions Of Recombinant Thrombomodulin And Activated Protein C And Their Neutralization By Factor Viii Inhibitor Bypass Activity (Feiba)
Walter Jeske1, Fakiha Siddiqui1, Zafar Siddiqui1, Debra Hoppensteadt1, Kazuhisa Tsuruta2, Jawed Fareed1
1Loyola University Chicago, Maywood, IL, United States, 2Asahi Kasei Pharma America, Waltham, MA, United States

P88
Reducing Unnecessary Coagulation Testing In Outpatients: A Quality Improvement Project
Fatima Khadadah1, Aziz Jiwajee2, Rosane Nisenbaum2,3, Hina Chaudry2, Paula James4, Curtis Handford1,2, Rajesh Girdhari1,2, Michelle Sholzberg1,2,3
1University of Toronto, Toronto, ON, Canada, 2St. Micheal's Hospital, Toronto, ON, Canada, 3Li Ka Shing Institute, Toronto, ON, Canada, 4Queen's University, Kingston, ON, Canada

P89
Real-World Adherence, Consumption, And Medical Resource Use Of Rfixfc Versus Rfix In Hemophilia B
Nanxin (Nick) Li, Christopher Barnowski, Jun Su
Bioverativ Therapeutics Inc, Waltham, MA, United States

P90
Pharmacokinetics, Efficacy, And Safety Of High-Purity Factor X For The Prophylactic Treatment Of Hereditary Factor X Deficiency
Ri Liesner1, James N Huang2, Kaan Kavakli3, Steven K Austin4, Jeanette Payne5, Kim Clark6, Chioma Akanezi7, Nuria Bermejo8, Martina Buehrlen9
1Haemophilia Comprehensive Care Centre, Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, 2Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, United States, 3Ege University Medicine Faculty, Izmir, Turkey, 4St. George's Haemophilia Centre, St. George's University Hospitals NHS Foundation Trust, London, United Kingdom, 5Department of Paediatric Haematology, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom, 6Bio Products Laboratory USA Inc., Durham, NC, United States, 7Bio Products Laboratory Ltd., Elstree, United Kingdom, 8Hospital San Pedro de Alcántara, Cáceres, Spain, 9Klinikum Bremen-Mitte, Prof-Hess-Kinderklinik, Bremen, Germany

P92
Do Hemophilia A Patients Treated With Turoctocog Alfa Prefer A Fviii Product With Portability Features? A Conjoint Analysis.
Juliana Setyawan1, Neeraj N. Iyer1, Jennifer Kirschenbaum2, Alison Currie2, Natalia Holot1, Yan Wang2
1Novo Nordisk, Inc., Plainsboro, NJ, United States, 2WG Group, New York, NY, United States

P93
Clinical Outcomes Related To Over The Wire Catheter Exchange In Picc Reinsertion
Adam Suleman1,2, Sheryl McDiarmid2,3
1University of Ottawa, Ottawa, ON, Canada, 2Ottawa Hospital Research Institute, Ottawa, ON, Canada, 3cThe Ottawa Hospital, Ottawa, ON, Canada

P94
Laboratory Assessment And Validation Of A Chromogenic Factor Viii Assay Kit
Julie I. Tange, Deepti M. Warad, Dong Chen, Rajiv K. Pruthi
Comprehensive Hemophilia Center and Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, United States

P95
Characterization Of An Exosite In C-Terminus Of The Activated Protein C Light Chain For Anticoagulant And Cytoprotective Activities
Atsuki Yamashita, John H. Griffin, Laurent O. Mosnier
The Scripps Research Institute, La Jolla, CA, United States

P96
Tolerability/Safety Of Feiba 50% Reduced Volume And Faster Infusion Rates: Rationale And Design Of Feiba Star Study In Patients With Hemophilia A Or B With Inhibitors
Talaha M. Ali1, Roberto Crea2, Katharina Wanek2, Viridiana Cano3
1Shire, Chicago, IL, United States, 2Shire, Vienna, Austria, 3Shire, Mexico City, Mexico

10:00 - 11:00 AMGrand 8-9
Short Talks: Anticoagulation/POC

Chair(s): Pall Onundarson
10:00
Feasibility And Safety Of A 12-Week Inr Follow-Up Protocol Over Two Years In An Anticoagulation Clinic
Andrea L. Porter1,2, Amanda R. Margolis1,2, Carla E. Staresinic1, Michael W. Nagy1, Rebecca R. Schoen3, Cheryl A. Ray1, Christopher D. Fletcher1,4
1William S. Middleton Memorial Veterans Hospital, Madison, WI, United States, 2University of Wisconsin - Madison School of Pharmacy, Madison, WI, United States, 3Texas Tech University Health Sciences Center School of Pharmacy - Dallas/Ft. Worth Campus, Dallas, TX, United States, 4University of Wisconsin School of Medicine and Public Health, Madison, WI, United States

10:15
Novel Optical Sensing Of Anticoagulation And Hemodilution: Towards Comprehensive Self-Testing In Patients
Diane M Tshikudi1, Markandey M Tripathi1, Zeinab Hajjarian1, Elizabeth M Van Cott 2, Seemantini K Nadkarni1
11Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States, 22Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

10:30
Monitoring Anticoagulation And Hemostasis In Cardiac Surgical Patients With A Drop Of Whole Blood At The Point-Of-Care Using A Portable Optical Sensor
Diane M Tshikudi1,2, Alexandra G Wirth1,2, Seemantini K Nadkarni1,2,3
1Wellman Center for Photomedicine, Boston, MA, United States, 2Massachusetts General Hospital , Boston, MA, United States, 3Harvard Medical School, Cambridge, MA, United States

10:45
A Portable Optical Sensor To Monitor Coagulation At The Point-Of-Care: A Validation Study
Alexandra G. Wirth, Diane M. Tshikudi, Seemantini K. Nadkarni
Wellman Center for Photomedicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States

10:00 - 11:00 AMGrand 10
Short Talks: Laboratory

Chair(s): Donna Castellone
10:00
A Novel Functional Assay Measuring Neutrophil Degranulation And Mmp Release For Anti-Pf4/Heparin Antibodies
Madelaine E. Duarte1, Sanjay Khandelwal1, John D. Lambris2, Edimara S. Reis2, Gowthami M. Arepally1, Grace M. Lee1
1Duke University Medical Center, Durham, NC, United States, 2University of Pennsylvania, Philadelphia, PA, United States

10:15
Procoagulant Phospholipid Dependent Clotting Time Can Serve As A New Tool For The Identification Of Multiple Myeloma Patients With Poor Treatment Response.
Despoina Fotiou1, Loula Papageorgiou2,3, Stella Salta2,3, Patrick Vandreden4, Evangelos Terpos1, Jawed Fareed5, Matthieu Grusse4, Ismail Elalamy2,3, Grigoris Gerotziafas2,3
1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, , Greece, 2Department of Haematology, Tenon University Hospital Assistance Publique Hopitaux de Paris, Paris, , France, 3Cancer Biology and Therapeutics, INSERM U938, Institut Universitaire de Cancerologie (IUC), Université Pierre et Marie Curie (UPMC), Sorbonne Universities, Paris, Faculté de Medecine Pierre et Marie Curie , Paris, , France, 4Stago, Genneuvilliers, , France, 5Cardiovascular Institute, Loyola University Chicago, Loyola University Medical Center , Maywood IL, , United States

10:30
Evaluation Of The Anticoagulant Effect Of Heparin In Low Antithrombin Human Plasma
Jingxuan Liu, Kristina Perry, Kun Qian, Stephen Huang, Kate Madigan
Alnylam Pharmaceuticals, Cambridge, MA, United States

10:45
Pharmacoeconomic Analysis Of Direct Thrombin Inhibitors Using Igg Specific Elisa Antibodies In Suspected Heparin Induced Thrombocytopenia
Sophie Samuel1, Mary F McGuire2, Jennifer Cortes1, Phillip Weeks1, Richard S Brown1, Andy Nguyen2, Miguel Escobar2
1Memorial Hermann Medical Center , Houston, TX, United States, 2University of Texas Medical School, Houston, TX, United States

10:00 - 11:00 AMGrand 12
Short Talks: Hemophilia

Chair(s): Maggie Ragni and Hope Wilson
10:00
Spk-8011: Preliminary Results From A Phase 1/2 Trial Of Investigational Gene Therapy For Hemophilia Confirm Persistency Of Stable Fviii Activity Beyond Six Months
Lindsey A George2, Margaret Ragni3, Spencer Sullivan5, Christian Barrett4, Benjamin Samelson-Jones2, Adam Cuker6, J. Fraser Wright1, Daniel J Hui1, Katie Wachtel1, Daniel Takefman1, Linda B Couto1, Kathleen Reape1, Marcus E Carr1, Federico Mingozzi1, Xavier M Anguela1, Katherine A High1
1Spark Therapeutics, Philadelohia, PA, United States, 2CHOP, Philadelphia, PA, United States, 3University of Pittsburgh, Pittsburgh, PA, United States, 4Virginia Commonwealth University, Richmond, VA, United States, 5Mississippi Center for Advanced Medicine, Madison, MS, United States, 6University of Pennsylvania, Philadelphia, PA, United States

10:15
Spk-9001: Adeno-Associated Virus Mediated Gene Transfer For Hemophilia B &Ndash; Sustained Fix Activity And Persistent Prophylactic Benefit At One Year
Lindsey A George1, Spencer K Sullivan2, Adam Giermasz3, Jonathan M Ducore3, Benjamin Samelson-Jones1, Jerome M Teital4, Adam Cuker5, Daniel J Hui6, Katie Wachtel6, Sylvia von Mackensen5, Linda B Couto6, Kathleen Reape6, Marcus E Carr6, Federico Mingozzi6, Xavier M Anguela6, Katherine A High6
1CHOP, Philadelphia, PA, United States, 2Mississippi Center for Advanced Medicine, Madison, MS, United States, 3University of California at Davis, Sacramento, CA, United States, 4University of Toronto, Toronto, ON, Canada, 5University of Pennsylvania, Philadelphia, PA, United States, 6University Medical Centre Hamburg-Eppendorf, Hamburg, , Germany, 7Spark Therapeutics, Philadelphia, PA, United States

10:30
Endogenous Fix Expression And Reduced Annual Bleed Rate Following Amt-060 (Aav-Hfix) In Adults With Severe Or Moderate-Severe Hemophilia B: Interim Results Up To 1.5 Years From A Phase I/Ii Dose-Escalation Study
F Leebeek1, K Meijer2, M Coppens3, P Kampmann4, R Klamroth5, R Schutgens6, G Castaman7, E Seifried8, J Schwable8, H Bonig9, E Sawyer10, W Miesbach9
1Erasmus University Medical Center, Rotterdam, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands, 3Academic Medical Center, Amsterdam, Netherlands, 4Rigshopitalet, Copenhagen, Denmark, 5Vivantes Klinikum, Berlin, Germany, 6University Medical Center, Utrecht, Netherlands, 7Azienda Ospedaliera Universitaria Careggi, Florence, Italy, 8German Red Cross Blood Service Baden-Wurttemberg-Hessen, Frankfurt, Germany, 9Universitatsklinikum Frankfurt, Frankfurt, Germany, 10uniQure biopharma, B.V., Amsterdam, Netherlands

10:45
A Novel Application Of Anti-Protein S Antibody In Adjunct Therapy For Hemophilia B
Hope P Wilson1, A'drianne Dorsey2, Rinku Majumder2
1Pediatric Hematology/Oncology and Hematopoietic Stem Cell Transplantation Louisiana State University Health Sciences Center (LSUHSC), New Orleans, LA, United States, 2Department of Biochemistry LSUHSC, New Orleans, LA, United States

10:00 - 11:00 AMGrand 13
Short Talks: Antithrombotic Therapy

Chair(s): Leonardo Brandao and María Cristina Guerrero de León
10:00
Improving Warfarin Management Through Pharmacy Lead Dose Capping For Patients &Ge;85 Years Old
Jonathan Falsetta1, Elissa Dipasquale2, Zachary Klein3, Alan Mensch1, Saquib Ibrahim1, Jaclene Dabbour1, David Rosenberg4
1Plainview Hospital, Northwell Health, Plainview, NY, United States, 2Department of Clinical Transformation, Northwell Health, New Hyde Park, NY, United States, 3Krasnoff Quality Management Institute, Northwell Health, New Hyde Park, NY, United States, 4Department of Medicine, Northwell Health, New Hyde Park, NY, United States

10:15
Trends In Oral Antiplatelet Use In Qatar
Iqrah M Qurishi1, Sara Hussein1, Ahmed Morsi2, Amr Fahmi2, Shaaban Mohammed2, Moza Al Hail2, Hazem Elewa1,2
1Qatar University, Doha, Qatar, 2Hamad Medical Corporation, Doha, Qatar

10:30
Lack Of Standardization Of The Anti-Factor Xa Activity And The Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time Therapeutic Ranges Used In The Monitoring Of Unfractionated Heparin
Pierre Toulon1, Motalib Smahi2, Neila De Pooter3
1Hematology, Pasteur University Hospital, Nice, France, 2Hematology, Simone Veil Hospital, Eaubonne, France, 3Hematology, Grasse Hospital, Grasse, France

10:45
Evaluation Of Rivaroxaban Prescription Adherence Rates At A Large Teaching Hospital
Tina Wang1, Michael Knauss1, Sweta M. Patel2, Mikhail Y. Akbashev3
1Grady Health System , Atlanta, GA, United States, 2Mercer University, Atlanta, GA, United States, 3Emory University, Atlanta, GA, United States

11:00 - 12:00 PMGrand 5-7
Friday Plenary

Chair(s): Michael Paidas, Shannon Carpenter, Cathy Hayward
11:00
Fda&Rsquo;S Role In Expediting The Development Of Novel Medical Products
Peter Marks
US Food And Drug Administration

11:30
Current Initiatives At The Nhlbi In Hemostasis Research
Donna DiMichele
National Heart, Lung and Blood Institute

12:00 - 2:00 PMGrand 1-2
Satellite Symposium Lunch- Genentech

12:00 - 2:00 PMGrand 3-4
Satellite Symposium Lunch- Novo Nordisk

2:00 - 3:30 PMGrand 5-7
Venous Thromboembolism: Can We Truly Prevent these Clots?

Chair(s): Lana Castellucci
2:00
How Long Should We Extend Vte Prophylaxis And With What Anticoagulant
Phil Wells
Ottawa Hospital

2:30
Preventing Vte In Cancer Patients
Rachel Rosovsky
Massachusetts General Hospital

3:00
Prevention Of Vte Sequelae: Pts And Cteph
Susan Kahn
McGill University

2:00 - 3:30 PMGrand 8-9
Product Switching in the Age of New Factor Replacement Therapies

Chair(s): Shannon Carpenter and Stacy Crouteau
2:00
Overview Of New Products
Manuel Carcao
Hospital for Sick Children

2:30
How I Use Pharmacokinetic Profiling And Economic Considerations
Stacy Croteau
Boston Children's Hospital

3:00
Nursing Speaker About Adherence And Switching
Jim Munn
University of Michigan

2:00 - 3:30 PMGrand 10-11
Point of Care Devices for Laboratory and Clinical Use

Chair(s): Dot Adcock and Wilbur Lam
2:00
Microfluidics And Coagulation
Scott Diamond
University of Pennsylvania

2:30
Engineering Microvasculature-On-Chip Models As Research-Enabling Systems For Hemostasis And Thrombosis
Wilbur Lam
Georgia Tech/Emory University School of Medicine

3:00
Red Blood Cell Adhesion To Heme-Activated Endothelial Cells In Microscale Flow
Umut Gurkan
Case Western Reserve University

3:30 - 4:15 PMPacific Ballroom
Poster Session and Exhibits

P98
Knowledge And Improvement Of Health Literacy And Numeracy In Adolescent Patients With Hemophilia A And B
Nidhi Bhatt1,2, Lisa Boggio1, Mindy Simpson1
1Rush University Medical Center, Chicago, IL, United States, 2University of Illinois at Chicago Hospitals, Chicago, IL, United States

P99
Evaluation Of Radiation-Induced Coagulopathy In Development Of A Minipig H-Ars Model
Jeremy Brower, Waylon Weber, Melanie Doyle-Eisele
Lovelace Biomedical, Albuquerque, NM, United States

P100
Evaluation Of A Dedicated Calibrator And Controls For Emicizumab Quantification
Walter Calhoon1, Mags McInerney1, Andreas Calatzis2, David Chen3, Joanne Adamkewicz3, Michael Morris1
1r2 Diagnostics, South Bend, IN, United States, 2Institute for Cardiovascular Prevention (IPEK), LMU, Munich, Germany, 3Genentech, South San Francisco, CA, United States

P101
Trauma Induced Coagulopathy (Tic) And Radiation Induced Coagulopathy (Ric): Similarities Between Systemic Dysfunctions In The Coagulation Cascade
Erika W. Davies, Ashley Cecere, John Esker, Mary Homer
Biomedical Advanced Research and Development Authority, Washington, DC, DC, United States

P102
The Impact Of Positive Thrombophilia Screening On Treatment And Management Of Provoked Deep Vein Thrombosis
Erin Grinich, Thomas DeLoughery, Kristina Haley
Oregon Health & Science University, Portland, OR, United States

P103
Changes In Blood Viscosity And Other Rheological Parameters Before And After Phlebotomy
Mina Hur1, Hanah Kim1, Mikyoung Park1, Hee-Jung Chung2
1Department of Laboratory Medicine, Konkuk University School of Medicine, Seoul, , Korea, 2Department of Laboratory Medicine, National Cancer Center Hospital, Goyang, , Korea

P104
A New Model For Risk Stratification Of Acute Pulmonary Embolism
Wei-Ying Jen1, Young Seok Jeon2, Pipin Kojodjojo3, Lynette Teo4, Mengling Feng2, Yen-Lin Chee1
1National University Cancer Institute, Singapore, Singapore, 2Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 3National University Heart Centre, Singapore, Singapore, 4National University Hospital, Singapore, Singapore

P105
Quality And Consequences Of Laboratory Monitoring For Von Willebrand Disease During Pregnancy
Dominder Kaur1, Sara K. Vesely2, Terah Koch1, Sarah H. O'Brien1,3
1Division of Pediatric Hematology/Oncology, Nationwide Children’s Hospital/The Ohio State University, Columbus, OH, United States, 2Department of Biostatistics and Epidemiology, College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States, 3Center for Innovation in Pediatric Practice, The Research Institute at Nationwide Children’s Hospital, Columbus, OH, United States

P106
A Theoretical Model To Predict The Real World Effectiveness Of Clotting Factor Concentrates.
Marc Lara1, Danielle Nance2, Maissaa Janbain3, Angela Kellum3, Michael Callaghan4
1MicroHealth, New York, NY, United States, 2Arizona Bleeding Disorders Health and Wellness Center, Phoenix, AZ, United States, 3Tulane University School of Medicine, New Orleans, LA, United States, 4Children's Hospital of Detroit, Detroit, MI, United States

P107
Acute Radiation Coagulopathy: Pro-Coagulant And Anti-Coagulant Responses Following Total Body Irradiation
Matt Lindeblad1, Vasilis Moustaferis1, Andre Paredes1, Yongmei Chen1, Rachana Patil1, David Benavidez1, Matthew Neal2, Alex Lyubimov1, Amelia Bartholomew1
1University of Illinois, Chicago, IL, United States, 2University of Pittsburgh, Pittsburgh, PA, United States

P109
Development Of A Hemophilia Distress Tool
Mary E. Michaels1, Vaughn Barry1, Shanna Mattis1, Mary Ellen Lynch2, Christine L. Kempton1
1Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, United States, 2Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States

P110
Burden Of Illness For Us Male Hemophilia A Or B Patients With Inhibitors: Insights From The Results Of The Choice Project Into Treatment, Pain Management, And Quality Of Life Issues
Wendy E. Owens1, Allan Alexander2, Anissa Cyhaniuk1, Kate Nyormoi2, Elaine Chan1, Janet Chupka1
1Hemophilia Federation of America, Washington, DC, United States, 2HEMA Biologics, LLC, Louisville, KY, United States, 3Hemophilia Federation of America, Washington, DC, United States, 4HEMA Biologics, LLC, Louisville, KY, United States, 5Hemophilia Federation of America, Washington, DC, United States, 6Hemophilia Federation of America, Washington, DC, United States

P112
Bay 94-9027 Prophylaxis Improves Activity And Work Productivity: Data From The Protect Viii Study
Mindy L. Simpson1, Shadan Lalezari2, Pavani Chalasani3, Despina Tseneklidou-Stoeter4, Olubunmi Afonja5, Monika Maas Enriquez6
1Rush University Medical Center, Chicago, IL, United States, 2Israel National Hemophilia Center, Chaim Sheba Medical Center, and Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel, 3University of Arizona Cancer Center, Tucson, AZ, United States, 4Bayer, Berlin, Germany, 5Bayer, Whippany, NJ, United States, 6Bayer, Wuppertal, Germany

P113
Two Alternative Methods For Determining Stabilized Dilute Russel Viper Venom Time Assay Cutoff Ratios
Melissa S. Stuart, Julie I. Tange, Rajiv K. Pruthi, MBBS, Dong Chen, M.D, PhD
Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, United States

P114
Bleeding Diathesis In A Patient With A Novel Mutation In Serpinf2: A Case Study Of Alpha-2 Antiplasmin Deficiency
Marcela D Torres1, L. Margaret Drummond-Borg2, Dorothy M Adcock3, K. Elissa Dunlap4
1Department of Hematology Oncology, Cook Children's Medical Center, Fort Worth, TX, United States, 2Department of Genetics, Cook Children's Medical Center, Fort Worth, TX, United States, 3Colorado Coagulation, Laboratory Corporation of America® Holdings, Englewood, CO, United States, 4Texas College of Osteopathic Medicine UNT Health Science Center, Fort Worth, TX, United States

P115
Safety And Efficacy Of N9-Gp, A Recombinant Glycopegylated Factor Ix With Extended Half-Life, In Us Vs Global Patients With Hemophilia B: Results From The Paradigm&Trade; Clinical Program
Guy Young1, Steven R Lentz2, Susan Kearney 3, Miguel Escobar4, Stephanie Seremetis 5, David Cooper5, Christopher Walsh6
1Hemostasis and Thrombosis Center, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, United States, 2Department of Internal Medicine, Carver College of Medicine, University of Iowa, Iowa City, IA, United States, 3Children’s Hospitals and Clinics of Minnesota Hemophilia and Thrombosis Center, Minneapolis, MN, United States, 4McGovern Medical School, University of Texas Health Science Center, Houston, TX, United States, 5Novo Nordisk Inc., Plainsboro, NJ, United States, 6Icahn School of Medicine at Mount Sinai, New York, NY, United States

P116
The Cost Of Implementing A Quality Improvement Pilot Program At The Hemophilia Center: Year One
Alysia A. Cox, Susan U. Lattimore, Michael Recht
The Hemophilia Center at Oregon Health & Science University, Portland, OR, United States

P117
Incidence Of Post-Operative Venous Thromboembolism By Patient Abo Blood Type In The Mayo Clinic Rochester National Surgical Quality Improvement Program Sample
Paul R Daniels1, Elizabeth A Gilman1, Karen F Mauck1, Amy E Glasgow2, Matthew A Bartlett1, Elizabeth B Habermann2
1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States, 2Department of Health Care Policy and Research, Mayo Clinic, Rochester, MN, United States

P118
Perinatal And Obstetric Outcomes Of A Patient With Aplastic Anemia During Pregnancy: A Case Report
MARIA CRISTINA GUERRERO DE LEON1, ADRIANA MARGARITA AMAYA WALLE1, CESAR HOMERO GUTIÉRREZ AGUIRRE1, JORGE EDUARDO CORRES COLLANTES1, RICARDO ESPARZA PEREZ1, EDMUNDO ERBEY CASTELAN MALDONADO2
1IMSS UMAE 23 HOSPITAL DE GINECOLOGIA Y OBSTETRICIA, Monterrey, Mexico, 2IMSS UNIDAD MEDICA DE ALTA ESPECIALIDAD, Monterrey, Mexico

P119
Quality Of Life Among Pediatric Patients With A Bleeding Disorder And Their Siblings: A Mixed Methods Examination.
Maria Lauer, Sunnye Mayes, Osman Khan
University of Oklahoma Health Sciences Center, Oklahoma City , OK, United States

P163
Differential Effects Of Anti-Angiogenic Treatments On Pathological Hypervascularity In Hemophilic Arthropathy
Tine L. Wyseure1, Atsuki Yamashita1, Esther J. Cooke1,2, Annette von Drygalski1,2, Laurent O. Mosnier1
1The Scripps Research Institute, La Jolla, CA, United States, 2University of California, San Diego, CA, United States

4:15 - 5:45 PMGrand 5-7
Bleeding and Clotting in the World of LVADs and ECMO

Chair(s): Hazem Elew and Lisa Baumann Kreuziger
4:15
When Thrombosis Happens
Lisa Baumann Kreuziger
BloodCenter of Wisconsin

4:45
When Bleeding Happens
Martin Strueber
Michigan State University

5:15
When It'S A Pediatric Patient
Mike Callaghan
Wayne State University School of Medicine

4:15 - 5:45 PMGrand 8-9
Thrombophilia and Laboratory Assessment of Anticoagulant Drugs

Chair(s): Chuck Eby and Nicole Zantek
Warfarin Pharmacogenetics? Bleeding Thrombosis And Inr Control
Charles Eby
Washington University School of Medicine

Doacs And Implications On Laboratory Results
Kandice Kottke Marchant
Cleveland Clinic

Choosing Wisely: If, When, What And How To Test For Thrombophilia
Nicole Zantek
University of Minnesota

4:15 - 5:45 PMGrand 10-11
New players in Thrombosis

Chair(s): Robert Sidonio and Shannon Meeks
4:15
Platelet Responses To Immune Complexes
Eric Boilard
Laval University, , QC, Canada

4:45
Protein Disulfide Isomerase
David Essex
Lewis Katz School of Medicine

5:15
Polyphosphate
Jim Morrissey
University of Michigan Med. School

5:45 - 6:30 PMPacific Ballroom
Poster Session/Exhibits

P121
Prevalence Of Microcytic Anemia In Females With Cerebrovascular Accidents
Anthony Betbadal1, Jahnavi Gollamudi2, Lalitha Nayak2
1Indiana University School of Medicine, Indianapolis, IN, United States, 2Division of Hematology and Oncology, Seidman Cancer Center, Cleveland, OH, United States

P122
Abdominal Vein Thrombosis In A Pediatric Tertiary Center: Epidemiology, Risk Factors, Characteristics And Outcome
Carrie E Diamond, Julie K Weisman, Carole Hennessey , Yaser A Diab
Children's National Health System, Department of Hematology/Oncology, Washington , DC, United States

P123
Cost Analyses Of Pediatric Thrombophilia Testing: A Report From The Children&Rsquo;S Hospital-Acquired Thrombosis Registry
Arash Mahajerin1, Michael Formica2, Joel Hay2, Brian Branchford3, Guy Young4, Emily Krava4, Julie Jaffray4
1CHOC Children's Hospital, Orange, CA, United States, 2School of Pharmacy University of Southern California, Los Angeles, CA, United States, 3University of Colorado, Denver, CO, United States, 4Children's Hospital Los Angeles, Los Angeles, CA, United States

P124
Characteristics And Outcomes Of Contraception-Related Venous Thromboembolism In Adolescents
Julie K Weisman, Carrie E Diamond, Jennifer Meldau, Yaser A Diab
Children's National Health System, Department of Hematology/Oncology, Washington, DC, United States

P125
Tpa Use And Relationship To Venous Thromboembolism In Pediatric Leukemia Patients
Katherine Armstrong M.D1, Elizabeth Mauer MS2, Linda M, Gerber PhD2, Nicole Kucine M.D1
1Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States, 2Department of Healthcare Policy & Research, Division of Biostatistics and Epidemiology, Weill Cornell Medicine, New York, NY, United States

P127
Effectiveness And Safety Of Rivaroxaban Versus Warfarin In Patients With Unprovoked Venous Thromboembolism
Craig I. Coleman1,2, Thomas J. Bunz3, W. Frank Peacock4, Brandon K. Martinez1,2, William L. Baker1,2
1University of Connecticut, Storrs, CT, United States, 2Hartford Hospital, Hartford, CT, United States, 3New England Health Analytics LLC, Granby, CT, United States, 4Baylor College of Medicine, Houston, TX, United States

P128
Direct Oral Anti-Coagulants In Patients With Venous Thromboembolism And Thrombophilia: A Systematic Review And Meta-Analysis
Maha Elsebaie1, Amelia Langston2, Manila Gaddh2
1Ain Shams University, Cairo, Egypt, 2Winship Cancer Institute of Emory University, Atlanta, GA, United States

P129
Utilization Of Direct-Acting Oral Anticoagulants At An Academic Medical Center
Gregory C Hadlock, Richard D'Angio, Lisa K Koselke, Shadi Mayasy, Taylor Goot, Allison E Burnett
University of New Mexico Hospitals, Albuquerque, NM, United States

P130
Postpartum Anticoagulation In Women With Mechanical Heart Valves
Roxanna A Irani1, Ann Santa-Ines2, Robert W Elder2, Heather S Lipkind1, Michael J Paidas1, Katherine H Campbell1
1Yale University School of Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, Division of Maternal-Fetal Medicine, New Haven, CT, United States, 2Yale University School of Medicine, Department of Pediatrics, Section of Pediatric Cardiology, New Haven, CT, United States

P131
Implementation Of An Alert To Prevent Use Of Antithrombotic Medications In The Presence Of Neuraxial Anesthesia
Benjamin Jung1, James Steffen1, David Eberle1, Craig Cummings2, Siddhartha Singh1,2, Lisa Baumann Kreuziger1,2,3
1Froedtert Hospital, Milwaukee, WI, United States, 2Medical College of Wisconsin, Milwaukee, WI, United States, 3BloodCenter of Wisconsin, Milwaukee, WI, United States

P132
Laboratory Validation Of A Chromogenic Anti-Xa Assay For Apixaban
Rachel R Leger, Julie I Tange, Robert D McBane, Dong Chen, Rajiv K Pruthi
Mayo Clinic, Rochester, MN, United States

P133
Indications, Outcomes And Assessment Of Guideline Adherence Of Inferior Vena Cava Filter Insertions - A Tertiary Care Center Experience
Farheen Manji1, Stefan Przybojewski2, Deepa Suryanarayan1
1Department of Medicine, Alberta Health Services, Calgary, AB, Canada, 2Department of Diagnostic Imaging, Alberta Health Services, Calgary, AB, Canada

P135
Relationship Between Thromboelastography And Anti-Xa Values In Heparinized Pediatric Patients
Amrom E. Obstfeld, Michele P. Lambert
Children's Hospital of Philadelphia, Philadelphia, PA, United States

P136
Treatment Of Venous Thromboembolism During Induction Chemotherapy In Patients With Acute Leukemia: A Single Center Experience
Bianca Patel1, En Cheng2, Morgan McLemore3, Martha Arellano3, Leonard T Heffner Jr3, Elliott F Winton3, Imre Bodo3, Amelia Langston3, Vamsi Kota3, Manila Gaddh3
1Summer Scholar Program, Winship Cancer Institute of Emory University, Atlanta, GA, United States, 2Emory University School of Medicine, Atlanta, GA, United States, 3Winship Cancer Institute of Emory University, Atlanta, GA, United States

P137
Reversal Of Anticoagulants And Antiplatelet Agents In A Community Hospital
Dmitriy Petrov, Rishin Handa, Tawagi Karine, Twylla Tassava
St Joseph Mercy Hospital , Ypsilanti, MI, United States

P138
Enoxaparin 20 Mg Daily For Thromboprophylaxis In Low Body Weight Patients
Christina Ruscio, Maura Wychowski, Peter Kouides, Ronald Sham
Rochester General Hospital, Rochester Regional Health, Rochester, NY, United States

P139
Pharmacoeconomic Analysis Of Direct Thrombin Inhibitors Using Polyspecific Elisa Antibodies In Suspected Heparin Induced Thrombocytopenia
Sophie Samuel1, Mary F McGuire2, Jennifer Cortes1, Phillp Weeks1, Richard S Brown1, Andy Nguyen2, Miguel Escobar2
1Memorial Hermann Medical Center, Houston, TX, United States, 2University of Texas Medical School., Houston, TX, United States

P140
Apixaban Levels In Extremely Obese Patients
Laura Talamo, Surabhi Palkimas, Lindsay Bazydlo, Hillary Maitland
University of Virginia, Charlottesville, VA, United States

P141
A Universal Heparin Reversal Agent Demonstrates Negligible Effect On Platelets, Endothelial Cells And Reverses Profibrinolytic Activity Of Heparin
Sreeparna Vappala1,2, Manu Thomas Kalathottukaren1,2, Usama Abbasi1,2, Srinivas Abbina1,2, Iren Constantinescu1,2, Charles A. Haynes1,3, Jayachandran N. Kizhakkedathu1,2,4
1Centre for Blood Research,University of British Columbia, Vancouver, BC, Canada, 2Department of pathology and laboratory medicine,University of British Columbia, Vancouver, BC, Canada, 3Chemical & Biological Engineering,University of British Columbia, Vancouver, BC, Canada, 4Department of Chemistry,University of British Columbia, Vancouver, BC, Canada

P142
Effect Of An Anticoagulation Stewardship Program On The Outcomes Of Warfarin Therapy
Maura K. Wychowski, Christina I. Ruscio, Ronald L. Sham, Peter A. Kouides
Rochester General Hospital, Rochester, NY, United States

P143
Performance Of A New Kit For A Modified Nijmegen-Bethesda Assay: Comparison Of A Chromogenic Versus A Clot-Based Factor Viii Inhibitor Assay In Plasma From Persons With Hemophilia A (Pwha)
Ali Sadeghi-Khomami1, Marc Boylan1, David C. Chen2, Joanne I. Adamkewicz2
1Precision BioLogic Inc., Dartmouth, NS, Canada, 2Genentech Inc., South San Francisco, CA, United States

P144
Evaluating Bleeding Disorder Knowledge In Patients With Hemophilia With Aims Toward Medical Independence
Ari B Vandersluis, Linda Casto, Charmaine Biega, Anne Gonzales, Claire Russel, Joseph Stanek, Elizabeth Varga, Pam Widener, Amy Dunn
Nationwide Children's Hospital, Columbus, OH, United States



Saturday, March 10, 2018


8:00 - 9:30 AMGrand 5-7
From Pregnancy to Pediatrics

Chair(s): Eric Grabowski and Julie Jaffray
8:00
Thrombotic Complications In Pregnancy And Use Of Lmwh As Prevention
Marc Rodger
Ottawa Hospital Research Institute

8:30
Perinatal Stroke: The Antenatal Experience
Michael Paidas
Yale University

9:00
Perinatal Stroke: Neonatal Experience
Eric F. Grabowski
Harvard Medical School

8:00 - 9:30 AMGrand 8-9
Top Five Basic Science and Clinical Papers Ever on Inhibitors

Chair(s): Robert Sidonio
8:00
Top 5 Basic Science Paper Ever
Shannon Meeks
Children's Healthcare of Atlanta

8:30
Top 5 Clinical Papers Ever
Donna DiMichele
National Heart, Lung and Blood Institute

9:00
Case Study
Christine Guelcher
Center for Cancer and Blood Disorders Children’s National Health System

8:00 - 9:30 AMGrand 10-11
Coagulation Tests: Update on Assays Used for Diagnosis and Guiding Therapy

Chair(s): Cathy Hayward and Rajiv Pruthi
8:00
Emergency And Perioperative Hemostasis Testing: Which Assays Provide Helpful Information
Wayne Chandler
Seattle Children's

8:30
Hus And Ttp Testing
Ken Friedman
Blood Center of Wisconsin

9:00
Updating Hemostasis Testing: What Labs Need To Be Aware Of For New Factor Replacement Products
Rajiv Pruthi
Mayo Clinic in Rochester

9:30 - 10:15 AMPacific Ballroom
Poster Session/Exhibits

Risk Of Venous Thromboembolism In Patients With Non-Hodgkin Lymphoma: A Single Center Retrospective Analysis
Sowjanya Vuyyala, Le Dung Ha, Gregory C Connolly, Thushara Paul
Rochester General Hospital, Rochester, NY, United States

P145
Higher Rates Of Bleeding And Use Of Treatment Products Among Pre-Adolescent Boys Compared To Girls With Von Willebrand Disease
Karon Abe1, Brandi Dupervil1, Sarah H. O'Brien2, Meredith Oakley1, Roshni Kulkarni3, Joan C. Gill4, Vanessa Byams1, Mike Soucie1
1Centers for Disease Control and Prevention, Atlanta, GA, United States, 2Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, United States, 3Centers for Bleeding and Clotting Disorders, Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, United States, 4Bloodcenter of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, United States

P146
Effects Of Preanalytical Heat Treatment In Factor Viii Inhibitor Assays On Factor Viii Antibody Levels
Brian Boylan, Connie H Miller
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, United States

P147
Differential Determination Of Innate Vs Recombinant Coagulation Factor 8 Activity Measurement Using Clot-Based Assay And Chromogenic Assays
Yamini S Bynagari, Hannah Newton, Jacob Cota, Sunghee Chang, Joey Azzolino, Mike Ero
Machaon Diagnostics, Oakland, CA, United States

P148
Characterization Of The Impact Of Prior Iti On Patient Outcomes In Haven1
Michael U. Callaghan1, Peter J. Kuebler2, Ling Gao3, Richard H. Ko2, Jenny Devenport2, Michael Liberman2
1Children’s Hospital of Michigan, Detroit, MI, United States, 2Genentech, Inc., South San Francisco, CA, United States, 3Analystat Cop, Warrant, NJ, United States

P149
Real-World Specialty Pharmacy Dispensation And Expenditures Associated With Standard And Extended Half-Life Recombinant Factor Ix Products Among Hemophilia B Patients Receiving On-Demand Regimens
Patrick F. Fogarty1, José Alvir1, Amit Chhabra1, Margaret McDonald1, Bartholomew J Tortella2, Andreas M Pleil3, Dean Spurden4
1Pfizer Inc, New York, NY, United States, 2Pfizer Inc, Collegeville, PA, United States, 3Pfizer Inc, San Diego, CA, United States, 4Pfizer Ltd, Tadworth, United Kingdom

P150
Dental Habits And Oral Health In Children And Young Adults With Bleeding Disorders: A Single-Institutional Cross-Sectional Study
Elizabeth Hastie1, Carol Shumake2, Brittany Waters2, Vaughn Barry1, Robert F. Sidonio1,2
1Emory University School of Medicine, Atlanta, GA, United States, 2Children's Healthcare of Atlanta, Atlanta, GA, United States

P151
Studying Racial Disparity In The Whole Blood And Plasma Of Healthy Volunteers Using Rotational Thromboelastometry
Maissaa Janbain1, Radia Ksayer1, John Lefante2, Karam Zakharia1, Anita Madison1, Cindy Leissinger1
1Tulane School of Medicine, New Orleans, LA, United States, 2Tulane School of Public Health and Tropical Medicine, New Orleans, LA, United States

P152
Case Report: Monoclonal Igm Λ Coagulation Inhibitor With Phosphatidylserine Specificity Interfering With Plasma, But Not Whole-Blood Based Coagulation Testing
Jing Jin1, Steven A. Baker2, Mia Shokry3, James L. Zehnder2
1Department of Special Coagulation Clinical laboratory, Stanford Health Care, Palo alto, CA, United States, 2Department of Pathology, School of Medicine, Stanford University , Stanford, CA, United States, 3Clovis North High School, Fresno, CA, United States

P153
Comparison Of Bleeding Rates Before And During Bay 94-9027 Prophylaxis: Data From The Protect Viii Study And Extension
Bryce A. Kerlin1, Mindy L. Simpson2, Mark T. Reding3, Camila Linardi4, Lawrence Schwartz4
1Nationwide Children’s Hospital, Columbus, OH, United States, 2Rush University Medical Center, Chicago, IL, United States, 3University of Minnesota Medical Center, Minneapolis, MN, United States, 4Bayer, Whippany, NJ, United States

P154
Differential Inhibitor Formation In The Absence Of Von Willebrand Factor
Hillary J. Larson1, Jason A. Taylor1,2
1Portland VA Medical Center, Portland, OR, United States, 2The Hemophilia center at OHSU, Portland, OR, United States

P155
Long-Term Outcomes Of Acquired Hemophilia A: A 16-Year Single Institution Prospective Cohort Experience
Justin Loloi, Morgan K Moroi, Natthapol Songdej, Hamid A Al-Mondhiry
Penn State College of Medicine, Hershey, PA, United States

P157
Desmopressin Challenge Testing In Children With Bleeding Disorders: How Much Is Enough?
Sarah A. Miller1, M. Brooke Bernhardt2, Donald L. Yee1, 2
1Baylor College of Medicine, Houston, TX, United States, 2Texas Children's Hospital, Houston, TX, United States

P158
Evaluation Of Mutation-Scoring Tools For Use In Assigning Inhibitor Risk Among Persons With Hemophilia A
Amanda B. Payne1, Connie H. Miller1, Dorothy Ellingsen1, Jennifer Driggers1, Christopher J. Bean1, Jennifer G. Mulle2,3, J. Michael Soucie1, HIRS Investigators4
1Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, Atlanta, GA, United States, 2Emory University, Rollins School of Public Health, Department of Epidemiology, Atlanta, GA, United States, 3Emory University, Laney Graduate School, Graduate Division of Biological and Biomedical Sciences, Atlanta, GA, United States, 4Multiple Locations, Atlanta, GA, United States

P159
Patient-Reported Outcomes In Hemophilia B Patients Treated With Ib1001 [Coagulation Factor Ix (Recombinant)]
David Schaaf1, Catherine Lockhart2, Rhonda Fritz1
1Aptevo Therapeutics, Seattle, WA, United States, 2Independent Consultant, Seattle, WA, United States

P160
Presentation And Management Of Autoimmune Factor V Inhibitors: The Mayo Clinic Experience
Meera Sridharan1, Kara A Fylling2, Aneel A Ashrani1,3, Laynalee K Cardel2, Dong Chen3, C Christopher Hook1, Ariela L Marshall1,3, William L Nichols1,3, Rajiv K Pruthi1,3
1Division of Hematology, Mayo Clinic, Rochester, MN, United States, 2Special Coagulation Laboratory, Mayo Clinic, Rochester, MN, United States, 3Deparment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States

P161
Validation Of A Chromogenic Nijmegen Bethesda Assay For The Measurement Of Fviii Inhibitor Titer In The Presence Of Emicizumab (Ace910)
Stefan Tiefenbacher1, Sangeeta Shrotriya1, Mary Robinson1, Diana Steinbuesch2, Joanne Adamkewicz3
1Colorado Coagulation, Laboratory Corporation of America® Holdings, Engelwood, CO, United States, 2F. Hoffmann – La Roche AG, Basel, Switzerland, 3Genentech, South San Francisco, CA, United States

P164
Real-World Utilization And Costs Of Extended Half-Life Factor Products In Pediatric Hemophilia B Patients On Prophylaxis Therapy
Kun Yang, Brieana Buckley, Brent Mathison
Bioverativ, Waltham, MA, United States

P165
Clinical Application Of Vwf:Collage Binding Assay/Vwf In The Diagnosis Of Von Willebrand Disease
Yunxiao Zhao, Yang He
The first affiliated hospitial of soochow university , Suzhou, China

P166
A Correlation Study Of Adamts13 Neutralizing And Non-Neutralizing Antibodies
Ronda A Crist1, Kristi J Smock1.2, George M Rodgers1,2,3, Nahla M Heikal1,2
1ARUP Institute for Clinical and Experimental Pathology®, Salt Lake City, UT, United States, 2Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, UT, United States, 3Department of Internal Medicine, University of Utah Health Sciences Center, Salt Lake City, UT, United States

P167
Relevance Of Inflammatory And Hemostatic Biomarkers With Inflammasomes In Septic Patients At Risk Of Developing Coagulopathy
Richard V. Green1, Grace H. Wegrzyn1, Amanda T. Walborn1, Robin David1, Susan Walborn1, Debra Hoppensteadt1, Matthew Rondina2, Jawed Fareed1
1Loyola University of Chicago, Stritch School of Medicine, Maywood, IL, United States, 2University of Utah Health Sciences Center, Salt Lake City, UT, United States

P168
The Fibres Study: A Phase 3, Non-Inferiority, Randomised Comparison Of A New Fibrinogen Concentrate Vs. Cryoprecipitate For Treating Acquired Hypofibrinogenaemia In Bleeding Cardiac Surgical Patients
Keyvan Karkouti
Toronto General Hospital, Toronto, ON, Canada

P169
Internal Medicine Trainees' Knowledge And Confidence In Using The American Society Of Hematology Choosing Wisely Guidelines In Hemostasis, Thrombosis, And Non-Malignant Hematology
Ariela L Marshall1, Sarah Jenkins1, Amy S Oxentenko1, Alfred Lee2, Mark D Siegel2, Joel T Katz3, Jatin Vyas4, John Del Valle5, Joseph R Mikhael6
1Mayo Clinic , Rochester, MN, United States, 2Yale University, New Haven, CT, United States, 3Brigham and Women's Hospital, Boston, MA, United States, 4Massachusetts General Hospital, Boston, MA, United States, 5University of Michigan, Ann Arbor, MI, United States, 6Mayo Clinic Arizona, Phoenix, AZ, United States

10:15 - 11:15 AMGrand 8-9
Short Talks: Hemostasis - Clinical/Translational II

Chair(s): Maggie Ragni and Lauren E. Amos
10:15
Understanding The Use Of Primary Thromboprophylaxis In Hospitalized Pediatric Patients
Lauren E. Amos1, Michael Silvey1, Matt Hall2, Char Witmer3, Shannon L. Carpenter1
1Children's Mercy Hospital, Kansas City, MO, United States, 2Children's Hospital Association, Lenexa, KS, United States, 3The Children's Hospital of Philadelphia, Philadelphia, PA, United States

10:30
Bleeding Risk Associated With Apixaban Compared With Warfarin In Patients With Severe Chronic Kidney Disease
Paul R Daniels, MD1, Kristen K Knoph, PharmD2, Kristina M Thurber, PharmD3, Narith N Ou, PharmD3, Dennis M Bierle, MD1, Ross A Dierkhising, MS4, Kristin C Mara, MS4, Raymond C Shields, MD5, John G O'Meara, PharmD3
1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, United States, 2Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA, United States, 3Department of Pharmacy Services, Mayo Clinic, Rochester, MN, United States, 4Department of Biostatistics and Informatics, Mayo Clinic , Rochester, MN, United States, 5Gonda Vascular Center, Mayo Clinic, Rochester, MN, United States

10:45
Prothrombin Complex Concentrate For Reversal Of Direct Factor Xa Inhibitors Prior To Emergency Surgery Or Invasive Procedure: A Retrospective Study
Siavash Piran, Caroline Gabriel, Sam Schulman
Department of Medicine, Division of Hematology and Thromboembolism, and Thrombosis and Atherosclerosis Research Institute, McMaster University, Hamilton, ON, Canada

11:00
The Use Of Prothrombin Complex Concentrate (Pcc) In A Community Hospital
Karine Tawagi, Ambreen Allana, Dmitryi Petrov, Anupam Suneja, Cherise Callahan, Twylla Tassava
St Joseph Mercy Ann Arbor, Ypsilanti, MI, United States

10:15 - 11:15 AMGrand 10
Short Talks: Platelets: Basic Science and Abstracts on Basic Science, Clinical and Laboratory Advances

Chair(s): Wolfgang Bergmeier and Larry Goldfinger
10:15
Platelet Responses In Placebo Patients With Long-Duration Chronic Immune Thrombocytopenia Initiating Fostamatinib In The 049 Open-Label Extension Study
James Bussel1, Alhossain Khalafallah2, Donald Arnold3, Nichola Cooper4, Michael A Boxer5, Keith McCrae6, Darla Liles7, Waleed Ghanima8, Hany Zayed9, Ben Cadieux9, Anne-Marie Duliege9
1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Weill Cornell Medicine, New York, NY, United States, 2Menzies Institute for Medical Research, University of Tasmania, Launceston, Tasmania, Australia, 3Michael G. DeGroote School of Medicine, Department of Medicine, McMaster, Hamilton, ON, Canada, 4Hammersmith Hospital, London, United Kingdom, 5Arizona Oncology Associates, Tucson, AZ, United States, 6Cleveland Clinic, Cleveland, OH, United States, 7Pitt County Memorial Hospital, Greenville, NC, United States, 8Sykehuset Østfold Kalnes, Grålum, Norway, 9Rigel Pharmaceuticals Inc., South San Francisco, CA, United States

10:30
Rap1A/B Isoforms Differentially Regulate Platelet Production.
Dorsaf Ghalloussi1, Ellen, C O'Shaughnessy2, David, S Paul1, Klaus Hahn2, Lucia Stefanini3, Robert, H Lee1, Koji Eto4, Wolfgang Bergmeier1
1UNC, Mc Allister Heart Institute, Chapel Hill, NC, United States, 2UNC, Pharmacology Department, Chapel Hill, NC, United States, 3Department of Internal and Specialized Medicine, Rome, Italy, 4Kyoto University, Kyoto, Japan

10:45
Implementation Of Whole Blood Impedance Aggregometry In Heparin-Induced Thrombocytopenia Laboratory Diagnosis Algorithm
Jing Jin1, Evan Hall2, Mia Shokry3, James Zehnder4
1Department of Special Coagulation Clinical laboratory, Stanford Health Care,, Palo alto, CA, United States, 2Department of Hematology/Oncology, School of Medicine, Stanford, CA, United States, 3Clovis North High School, Fresno, CA, United States, 4Department of Pathology, School of Medicine, Stanford University, Stanford, CA, United States

11:00
Atypical Laboratory Findings And Varying Bleeding Scores In Patients Diagnosed With Delta Granule Platelet Storage Pool Disorder; A Retrospective Chart Review Of 80 Pediatric Patients
Colleen A Mathews1, Charles N Nessle1, Arun R Panigrahi1, 2, Soutik Ghosal1, John A Meyers1, David S Taylor1, Ashok Raj1, Diane H Burnett1, Laura W Massie1
1University of Louisville, Louisville, KY, United States, 2University of California, Davis, Sacramento, CA, United States

10:15 - 11:15 AMGrand 12
Short Talks: Thrombosis - Basic Science

Chair(s): Eric Grabowski and Peter Doan
10:15
Association Between Variants In Hrg And Serpina10 With Male Gender In Patients With Venous Thromboembolism
Rahul M. Dhodapkar, Daniel J. Dykas, Deqiong Ma, Alfred I. Lee
Yale University, New Haven, CT, United States

10:30
Temporal And Anatomic Relationship Between Superficial And Deep Vein Thromboses In Hospitalized Children
Peter Doan, Emily Southard, Allaura Cox, Bryce Clark, Beth Wathen, Kenneth Hammett, Brian Branchford
Department of Pediatric Hematology/Oncology/Bone Marrow Transplant, University of Colorado School of Medicine, Aurora, CO, United States

10:45
Hit Antigenic Pf4/Heparin Complexes Activate Complement By The Classical Pathway
Sanjay Khandelwal1, Joann Ravi1, Grace M. Lee1, Lubica Rauova2, Mortimer Poncz2, Michael M. Frank3, Douglas B. Cines4, Gowthami M. Arepally1
1Division of Hematology, Duke University Medical Center, Durham, NC, United States, 2Children’s Hospital of Philadelphia, Philadelphia, PA, United States, 3Department of Pediatrics and Immunology, Duke University Medical Center, Durham, NC, United States, 4Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

11:00
Accelerated Venous Thrombosis, Enhanced Fibrin Deposition And Platelet Accumulation In A Mouse Model Of Sickle Cell Diesease
Erica M. Sparkenbaugh1, Camille Romanet-Faes1Romanet1,2, Brian Cooley3, Rafal Pawlinski1
1Division of Hematology/Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, Chapel Hill, NC, United States, 2MCF, Université Lyon 1, Laboratoire LIBM EA 7424, Lyon, France, 33Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

10:15 - 11:15 AMGrand 13
Short Talks: Hemostasis: Basic Science/Clinical

Chair(s): Marvin Neiman
10:15
Dosing Considerations In The Use Of Recombinant Von Willebrand Factor For Treatment Of Patients With Severe Von Willebrand Disease
Joan Cox Gill1, Pier M. Mannucci2, Giancarlo Castaman3, Flora Peyvandi2, Bettina Ploder4, Aaron Novack5, Peter Chen5, Arthur Sytkowski6, Bruce Ewenstein6
1Blood Research Institute, BloodCenter of Wisconsin and Medical College of Wisconsin, Milwaukee, WI, United States, 2Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico University of Milan, Milan, Italy, 3Center for Bleeding Disorders and Coagulation, Department of Oncology, Careggi University Hospital, Florence, Italy, 4Shire, Vienna, Austria, 5Shire, Chicago, IL, United States, 6Shire, Cambridge, MA, United States

10:30
Safe And Effective Platelet-Targeted Gene Therapy Of Hemophilia A Enabled Using Non-Genotoxic, Immunotoxin-Based Conditioning
Chunyan Gao1, Jocelyn A. Schroeder1, Agnieszka Czechowicz2, Qizhen Shi1
1Medical College of Wisconsin, Blood Research Institute, Children’s Research Institute, Milwaukee, WI, United States, 2Department of Pediatrics Division of Stem Cell Transplantation and Regenerative Medicine, Stanford University, Stanford University, CA, United States

10:45
The Impact Of Factor Viii Replacement On Osteoblast Development
Emily A. Larson1, Jason A. Taylor1,2
1Portland VA Medical Center, Portland, OR, United States, 2The Hemophilia Center at OHSU, Portland, OR, United States

11:00
Differential Modulation Of Plasminogen Activator Mediated Thrombolysis By Recombinant Thrombomodulin And Activated Protein C
Zafar Siddiqui1, Jawed Fareed1, Sanchayana Raghuvir1, Omer Iqbal1, Debra Hoppensteadt1, Kosuke Tanaka2, Kazuhisa Tsuruta2
1Loyola University Chicago, Maywoood, IL, United States, 2Asahi Kasei Pharma America, Waltham, MA, United States

11:15 - 12:30 PMGrand 5-7
Saturday Plenary: Difficult Cases

Chair(s): Michael Paidas, Shannon Carpenter, Cathy Hayward
Difficult Cases Panel
Peter Kouides 1, Barbara Konkle 2, Scott Kaatz3, Michael Paidas4, Salley Pels5, Richard Marlar 6
1University of Rochester School of Medicine, 2Puget Sound Blood Center, 3Henry Ford Hospital, 4Yale University School of Medicine, 5Yale University, 6University of New Mexico

12:30 - 12:40 PMGrand 5-7
Conference Wrap-up